Von Hippel-Lindau Disease

MONDO:0008667 Pathograph 16 Show in embeddings browser hereditary cancer-predisposing syndrome

Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome caused by germline pathogenic variants in the VHL tumor suppressor gene. It is characterized by the development of highly vascularized tumors including clear cell renal cell carcinoma, hemangioblastomas of the CNS and retina, pheochromocytomas, and pancreatic neuroendocrine tumors. VHL disease exemplifies the two-hit hypothesis for tumor suppressor genes and the role of hypoxia signaling dysregulation in tumorigenesis through constitutive HIF activation.

Ask OpenScientist

Ask a research question about Von Hippel-Lindau Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
8
Phenotypes
1
Hypotheses
4
Gaps
16
Pathograph
1
Genes
4
Medical Actions
4
Subtypes
13
References
1
Deep Research
1
Hyp. Reports
◆

Subtypes

4
VHL Type 1
Characterized by low risk of pheochromocytoma but high risk of renal cell carcinoma, hemangioblastomas, and pancreatic tumors. Associated with truncating mutations, large deletions, and missense mutations affecting HIF binding.
VHL Type 2A
Characterized by pheochromocytoma and hemangioblastomas but low risk of renal cell carcinoma. Associated with specific missense mutations.
VHL Type 2B
High risk of all VHL-associated tumors including pheochromocytoma, renal cell carcinoma, and hemangioblastomas. Associated with specific missense mutations.
VHL Type 2C
Pheochromocytoma only, without other VHL manifestations. Associated with specific missense mutations that retain some HIF regulatory function.
◈

Mechanistic Hypotheses

1
Canonical VHL Loss / HIF Pseudohypoxia / Vascular Tumor Predisposition Model
canonical_vhl_hif_pseudohypoxia_tumor_model CANONICAL
Evidence balance 4 support
Von Hippel-Lindau (VHL) disease is caused by germline heterozygous loss-of-function variants in VHL on 3p25.3. The VHL protein is the substrate recognition subunit of an E3 ubiquitin ligase complex that targets prolyl-hydroxylated HIF-1α/2α for degradation under normoxic conditions. Biallelic VHL inactivation ('second hit') in susceptible tissues stabilizes HIF-α despite normal oxygen levels — a 'pseudohypoxic' state — and drives constitutive transcription of VEGF, PDGF, EPO, TGF-α, and other pro-angiogenic and growth-promoting factors. This produces the canonical VHL tumor spectrum: retinal and CNS hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, and endolymphatic sac tumors. The HIF-2α-selective inhibitor belzutifan (FDA-approved 2021) shrinks VHL-associated tumors, providing direct pharmacologic validation of the HIF-pseudohypoxia axis as the canonical pathogenic mechanism.
Retained as CANONICAL with four mandatory qualifier annotations. The 2026 openscientist hypothesis-search report (kb/hypotheses/Von_Hippel-Lindau_Disease/canonical_vhl_hif_pseudohypoxia_tumor_model) finds STRONGLY SUPPORTED across five convergent evidence layers: (1) Mendelian genetics with ~95% penetrance by age 60; (2) atomic-resolution VHL-hydroxyproline crystal structures defining the oxygen-sensing mechanism; (3) FDA-approved belzutifan (HIF-2α inhibitor) demonstrating durable tumor shrinkage across all VHL-associated tumor types; (4) acquired on-target resistance mutations in the HIF-2α gatekeeper pocket confirming core HIF-2 dependency; (5) GWAS identification of EPAS1/HIF-2α as a sporadic RCC susceptibility locus, linking hereditary and sporadic pathogenesis. Four mandatory qualifications: (1) HIF-2α (NOT HIF-1α) is the specific oncogenic isoform in ccRCC, while HIF-1α functions as a bona fide tumor suppressor on chromosome 14q; (2) type 2C VHL mutations cause pheochromocytoma DESPITE retaining normal HIF-α ubiquitylation, proving the existence of HIF-INDEPENDENT tumor-suppressor functions of pVHL; (3) VHL loss alone is necessary but INSUFFICIENT for ccRCC — cooperating mutations in 3p chromatin remodeling genes (PBRM1, BAP1, SETD2) are required co-drivers that define distinct molecular and prognostic subtypes; (4) the tissue specificity of VHL disease — why only certain organs develop tumors despite ubiquitous VHL expression — remains mechanistically unexplained. Belzutifan FDA approval (2021) provides the strongest pharmacologic validation of the HIF-pseudohypoxia axis.
Deep research
OpenScientist citations 41 citations 2026-05-25T12:59:48.899496
Show evidence (4 references)
PMID:37980175 SUPPORT Other
"von Hippel-Lindau (VHL) disease is characterized by biallelic inactivation of the VHL gene leading to abnormal or absent VHL protein function, and constitutive activation of hypoxia-inducible factors (HIF) that leads to pro-tumorigenic sign"
Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.
PMID:22037472 SUPPORT In Vitro
"In this article, we identify focal, homozygous deletions of the HIF1α locus on 14q in clear cell renal carcinoma cell lines. Wild-type HIF1α suppresses renal carcinoma growth, but the products of these altered loci do not."
Backs qualifier 1 in the notes above. HIF-1α behaves as a kidney cancer suppressor rather than an oncogenic driver, so the oncogenic isoform in ccRCC is specifically HIF-2α and an undifferentiated reference to HIF-alpha stabilization is imprecise.
PMID:36253570 SUPPORT Other
"However, loss of VHL alone is often insufficient to drive oncogenesis. Results from genomic studies have shown that co-deletions of VHL with one (or more) of three genes encoding proteins involved in chromatin modification and remodelling, polybromo-1 gene (PBRM1), BRCA1-associated protein 1..."
Backs qualifier 3 in the notes above: VHL inactivation establishes pseudohypoxia but is often not sufficient on its own for clear cell renal carcinoma, which typically also carries a 3p chromatin-modifier co-deletion.
+ 1 more reference
?

Discussions and Knowledge Gaps

4
Why do only retina, CNS, kidney, adrenal medulla, pancreas and endolymphatic sac form tumors after biallelic VHL loss, when VHL is expressed and lost in every tissue?
KNOWLEDGE GAP OPEN vhl_tissue_tropism_unexplained
Attached to
pathophysiology#Tumor Development
This entry's causal chain runs from VHL loss through pseudohypoxia to a permissive growth environment and then simply asserts that "different tissues show variable susceptibility". That sentence is the gap, not an explanation of it. Nothing in the chain predicts which organs are at risk, and the somatic second hit is not obviously restricted to those organs, so tissue tropism has to come from a cofactor the model does not name. Candidates that have been raised include lineage-restricted enhancer accessibility at HIF-2alpha target loci, a developmentally arrested precursor population that persists only at certain sites, and tissue-specific tolerance thresholds for HIF-2alpha output. Resolving it matters clinically because surveillance protocols are currently organ lists derived from observed incidence rather than from mechanism.
Proposed experiments
Single-cell multi-omic comparison of VHL-susceptible and VHL-resistant tissues
vhl_single_cell_susceptible_vs_resistant_tissue
Paired single-cell RNA-seq and ATAC-seq on tissues that do and do not form VHL tumors (kidney proximal tubule, retinal progenitors, cerebellar molecular layer, adrenal medulla versus hepatocytes and skin fibroblasts), from VHL patients and controls, stratified by VHL genotype class.
Would support
pathophysiology#Tumor Development
Supporting outcome
  • Susceptible tissues show open, HIF-2alpha-responsive enhancer landscapes and higher HIF-2alpha target expression per unit of HIF-2alpha protein than resistant tissues do, identifying a chromatin-level cofactor that co-segregates with the observed organ list.
Refuting outcome
  • Enhancer accessibility and HIF-2alpha target output are comparable in susceptible and resistant tissues, which would move the explanation away from transcriptional competence toward cell-of-origin availability or differential rates of the somatic second hit.
Which pVHL activity, other than HIF-alpha ubiquitylation, is lost in type 2C mutants and drives chromaffin cell transformation?
KNOWLEDGE GAP OPEN vhl_type2c_hif_independent_effector_unknown
Attached to
pathophysiology#HIF-Independent pVHL Function Loss has_subtypes#VHL Type 2C
The dissociation is established: pheochromocytoma-only alleles ubiquitylate HIF-alpha normally and bind pVHL partners normally, yet still cause disease. What is missing is the effector. Fibronectin and extracellular matrix assembly, primary cilium maintenance, apoptosis and senescence control, and SOCS-mediated JAK regulation have all been proposed as HIF-independent pVHL functions, but no cited study isolates one of them as the type 2C lesion. Until that is settled, the pheochromocytoma arm of this entry rests on a node defined by what it is not. A quantitative interactome comparison of wild-type against type 1, type 2B and type 2C pVHL in chromaffin-lineage cells is the obvious discriminating experiment, followed by knockout of any partner lost selectively by type 2C mutants.
Show evidence (1 reference)
PMID:11331613 SUPPORT In Vitro
"Mutations associated with the PHE-only phenotype (type 2C) promoted HIF-alpha ubiquitylation in vitro and demonstrated wild-type binding patterns with pVHL interacting proteins, suggesting that loss of other pVHL functions are necessary for PHE susceptibility."
Establishes the dissociation that creates the gap, and shows that the type 2C alleles were not distinguishable from wild type on the interactor panel tested, so the responsible partner was not among them.
Conditional Vhl knockout mice reproduce HIF-driven vascular lesions but not retinal or cerebellar hemangioblastoma or clear cell renal carcinoma, so how much of the mechanism inferred from those models transfers to human VHL disease?
HUMAN MODEL MISMATCH OPEN vhl_mouse_models_miss_human_tumor_spectrum
Attached to
pathophysiology#Tumor Development phenotypes#Retinal Hemangioblastoma
Much of what is asserted about tumor initiation downstream of VHL loss comes from mouse conditional knockouts, and those models do not develop the human disease's defining lesions. No published model develops retinal hemangioblastoma, which is the most common clinical manifestation in patients. The mouse lesions that do appear are largely hepatic hemangiomas, a site VHL patients rarely present with. So the model system that supplies the mechanistic detail is not the model system that reproduces the disease, and mechanisms read off those mice describe what losing Vhl can do in mouse tissue rather than what is happening in a patient's retina or kidney. This sits directly underneath the tissue-tropism gap above: whatever explains why only some human organs are susceptible may also explain why mouse organs are susceptible in a different pattern.
Show evidence (1 reference)
PMID:22763871 SUPPORT Model Organism
"These models, despite advancing our understanding the molecular role of VHL, are by and large unable to recapitulate the more common features of human VHL disease. Up to date, no model exists that develop retinal hemangioblastomas, the most common clinical manifestation."
A review of fifteen years of Vhl-inactivation models stating that they do not reproduce the common human manifestations, and that no model develops retinal hemangioblastoma.
What molecular features determine why belzutifan clears every evaluable retinal hemangioblastoma but produces an objective response in roughly a quarter of advanced pheochromocytomas and paragangliomas?
KNOWLEDGE GAP OPEN vhl_belzutifan_response_determinants
Attached to
treatments#Belzutifan
The spread in response rate across tumor types is large enough that it is unlikely to be tissue accessibility alone, and it is the practical question for anyone deciding whether to offer belzutifan instead of surgery for a given lesion. Two determinants of resistance are established, both at the level of HIF-2alpha itself: an acquired gatekeeper substitution in the drug-binding pocket, and a SOCS3/JAK1/STAT3 enhancer circuit that raises EPAS1 transcription and so can outrun a drug that acts on the protein. What is not established is whether either predicts response prospectively, or whether the cross-tissue gradient instead tracks HIF-2alpha dependency, 14q/HIF1A status, or chromatin-modifier genotype. Pre-treatment biopsy profiling across tumor types and VHL genotype classes, correlated with response, is the study that would settle it.
Show evidence (2 references)
PMID:31727677 SUPPORT Human Clinical
"Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2α, which interferes with drug binding and precluded HIF-2 complex dissociation."
One established resistance route, at the drug-binding pocket itself, found in patients on prolonged HIF-2 inhibitor therapy.
PMID:41874563 SUPPORT In Vitro
"Using a genome-wide CRISPR screen in von Hippel-Lindau-deficient (VHL-deficient) ccRCC cells, we identified SOCS3 as a key negative regulator of HIF-2α."
A second, transcriptional route to sustained HIF-2alpha that acts upstream of the protein the drug binds. Cell-line and xenograft work in VHL-deficient clear cell renal carcinoma; not yet tested in patients progressing on belzutifan.
⚙

Pathophysiology

8
VHL Tumor Suppressor Loss
Germline heterozygous VHL mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates VHL function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.
cellular response to hypoxia GO:0071456 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cellular response to hypoxia (GO:0071456). GO:0071456 is a biological process from the Gene Ontology.
Downstream
Loss of HIF Degradation VHL loss prevents ubiquitination of HIF-alpha subunits
HIF-Independent pVHL Function Loss The same loss of pVHL also removes its HIF-independent activities, which is the arm that pheochromocytoma-only (type 2C) alleles implicate.
Chromatin Remodeler Co-Driver Loss The somatic second hit is usually loss of heterozygosity across the whole 3p arm, which co-deletes the neighbouring chromatin modifiers along with VHL.
Show evidence (1 reference)
PMID:37980175 SUPPORT
"von Hippel-Lindau (VHL) disease is characterized by biallelic inactivation of the VHL gene leading to abnormal or absent VHL protein function, and constitutive activation of hypoxia-inducible factors (HIF) that leads to pro-tumorigenic signaling."
Confirms that biallelic VHL inactivation (consistent with two-hit hypothesis) leads to constitutive HIF activation and pro-tumorigenic signaling.
Loss of HIF Degradation
VHL protein (pVHL) functions as the substrate recognition component of an E3 ubiquitin ligase complex that targets hydroxylated HIF-alpha subunits for proteasomal degradation under normoxic conditions. Loss of VHL function prevents HIF-alpha degradation, allowing HIF accumulation even in the presence of oxygen.
proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161). GO:0043161 is a biological process from the Gene Ontology.
Downstream
Constitutive HIF Activation Stabilized HIF-alpha accumulates and activates target genes
Show evidence (3 references)
PMID:19671042 SUPPORT
"The von-Hippel Lindau tumor suppressor (pVHL) is the substrate recognition component of an E3 ubiquitin ligase and functions as a master regulator of HIF activity by targeting the hydroxylated HIF-alpha subunit for ubiquitylation and rapid proteasomal degradation under normoxic conditions."
Defines pVHL as the substrate recognition component of an E3 ubiquitin ligase that targets hydroxylated HIF-alpha for proteasomal degradation.
PMID:15162797 SUPPORT
"VHL tumor suppressor is a specific substrate-recognition component of the E3 ubiquitin complex, which regulates proteasomal degradation of the subunit of the hypoxia inducible transcription factor (HIF). Impaired VHL complex function leads to accumulation of HIF, overexpression of various..."
Confirms that impaired VHL function leads to HIF accumulation due to loss of proteasomal degradation.
PMID:12050673 SUPPORT In Vitro
"The crystal structure of a hydroxylated HIF-1 alpha peptide bound to VCB (pVHL, elongins C and B) and solution binding assays reveal a single, conserved hydroxyproline-binding pocket in pVHL."
Gives the step its structural basis: capture of HIF-alpha by pVHL runs through one conserved pocket that reads the hydroxyproline mark, which is what beta-domain VHL mutations disrupt.
Constitutive HIF Activation
Stabilized HIF-alpha (primarily HIF-2alpha in RCC) dimerizes with HIF-1beta (ARNT) and translocates to the nucleus where it activates transcription of hypoxia-responsive genes. This occurs constitutively regardless of oxygen levels, creating a pseudo-hypoxic state. The two alpha isoforms are not interchangeable here: HIF-2alpha is the oncogenic driver, and pharmacologic and genetic work in clear cell renal carcinoma places the tumor's dependency specifically on HIF-2 rather than on HIF-alpha generically.
response to hypoxia GO:0001666 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to hypoxia (GO:0001666). GO:0001666 is a biological process from the Gene Ontology.
Downstream
VEGF Overexpression and Angiogenesis HIF activates VEGF transcription driving neovascularization
Growth Factor and Metabolic Reprogramming HIF activates genes promoting proliferation and altered metabolism
Show evidence (2 references)
PMID:11114720 SUPPORT In Vitro
"in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1alpha and HIF-2alpha proteins under normoxic conditions."
Demonstrates that VHL deficiency leads to constitutive HIF-alpha expression even under normoxic conditions, and that VHL restoration can reverse this effect.
PMID:31727677 SUPPORT INDIRECT Human Clinical
"Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2α, which interferes with drug binding and precluded HIF-2 complex dissociation."
Resistance arising through a gatekeeper substitution in the drug-binding pocket of HIF-2alpha itself is on-target genetic evidence that the tumor depends on HIF-2 activity, which is why this node names HIF-2alpha rather than HIF-alpha generically. Indirect because the inference runs from an acquired drug-resistance allele back to the driver.
VEGF Overexpression and Angiogenesis
VEGF (vascular endothelial growth factor) is a direct HIF target gene. Constitutive HIF activation leads to chronic VEGF overexpression, driving extensive tumor angiogenesis. This explains the highly vascular nature of VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.
vascular endothelial growth factor signaling pathway GO:0038084 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased vascular endothelial growth factor signaling pathway (GO:0038084). GO:0038084 is a biological process from the Gene Ontology. angiogenesis GO:0001525 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased angiogenesis (GO:0001525). GO:0001525 is a biological process from the Gene Ontology.
Downstream
Tumor Development Neovascularization supports tumor growth and progression
Show evidence (3 references)
PMID:11114720 SUPPORT
"In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2alpha mRNA in stromal cells of the tumors."
Demonstrates elevated VEGF levels in VHL-associated hemangioblastomas, linking HIF activation to VEGF overexpression.
PMID:11114720 SUPPORT
"The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1alpha and HIF-2alpha proteins."
Confirms VHL protein regulates angiogenesis through HIF-mediated mechanisms.
PMID:9787178 SUPPORT Human Clinical
"Surprisingly, we observed Epo mRNA expression in all hemangioblastoma specimens analyzed, but in none of four glioblastomas. In contrast, VEGF mRNA was expressed in all hemangioblastomas and all glioblastomas. In situ hybridization revealed neoplastic stromal cells as Epo- and VEGF-producing..."
Locates the pseudohypoxic transcriptional output in the tumor cell itself. Two HIF target genes are co-expressed by the neoplastic stromal cells of all 11 hemangioblastomas examined, in a non-hypoxic microenvironment, and the EPO signal separates hemangioblastoma from glioblastoma. This is the erythropoietin arm of the hypothesis, which the entry otherwise asserted without a citation.
Growth Factor and Metabolic Reprogramming
HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1, and glycolytic enzymes. This promotes cell proliferation, survival, and a shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.
cellular glucose homeostasis GO:0001678 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cellular glucose homeostasis, annotated with intracellular glucose homeostasis (GO:0001678). GO:0001678 is a biological process from the Gene Ontology. cell population proliferation GO:0008283 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology.
Downstream
Tumor Development Growth factors and metabolic changes drive tumorigenesis
Show evidence (1 reference)
PMID:37980175 SUPPORT
"immunohistochemical studies for markers such as paired box 8 (PAX-8), carbonic anhydrase 9 (CA9), and glucose transporter 1 (GLUT-1) have an important role in routine clinical practice and represent cost-effective diagnostic tools."
The use of GLUT-1 as a diagnostic marker for VHL-associated tumors reflects HIF-induced metabolic reprogramming with increased glucose uptake.
Tumor Development
The combination of increased angiogenesis, growth factor signaling, and metabolic reprogramming creates a permissive environment for tumor development. Different tissues show variable susceptibility, explaining the characteristic tumor spectrum of VHL disease including RCC, hemangioblastomas, and pheochromocytomas.
Downstream
Clear Cell Renal Cell Carcinoma VHL loss and HIF activation predispose renal tubular epithelium to clear cell RCC.
Cerebellar Hemangioblastoma Highly vascular CNS hemangioblastomas are part of the VHL tumor spectrum.
Retinal Hemangioblastoma Retinal capillary hemangioblastomas are part of the VHL vascular tumor spectrum.
Pheochromocytoma VHL-associated tumor susceptibility includes adrenal and extra-adrenal chromaffin tumors.
Pancreatic Neuroendocrine Tumor VHL tumor susceptibility includes pancreatic endocrine/neuroendocrine tumors.
Renal Cysts VHL-associated renal lesions include cystic kidney disease.
Pancreatic Cysts VHL-associated pancreatobiliary lesions include pancreatic cystic disease.
Endolymphatic sac tumor VHL tumor susceptibility can involve the endolymphatic sac of the inner ear.
Show evidence (2 references)
PMID:19671042 SUPPORT
"Mutations in pVHL can be found in familial and sporadic hemangioblastomas, clear cell carcinomas of the kidney, pheochromocytomas and inherited forms of erythrocytosis, illustrating the importance of disrupted molecular oxygen sensing in the pathogenesis of these diseases."
Documents the characteristic tumor spectrum of VHL disease and links it to disrupted oxygen sensing.
PMID:15162797 SUPPORT
"Loss of von Hippel-Lindau (VHL) protein function results in an autosomal-dominant cancer syndrome known as VHL disease, which manifests as angiomas of the retina, hemangioblastomas of the central nervous system, renal clear-cell carcinomas and pheochromocytomas."
Confirms the characteristic tumor spectrum associated with VHL protein loss.
HIF-Independent pVHL Function Loss
pVHL has activities beyond HIF-alpha ubiquitylation, including fibronectin and extracellular matrix assembly, primary cilium maintenance, and regulation of JAK/STAT signalling through SOCS proteins. Loss of these activities is a separate arm of VHL pathogenesis from pseudohypoxia. The evidence that it matters clinically comes from the genotype-phenotype boundary: the alleles that produce pheochromocytoma without hemangioblastoma or renal carcinoma (type 2C) still ubiquitylate HIF-alpha normally and still bind pVHL partners normally, so something other than HIF dysregulation must be driving chromaffin-cell transformation in those families. Which pVHL activity that is has not been established.
Downstream
Pheochromocytoma The arm of VHL pathogenesis that type 2C alleles implicate in adrenal and extra-adrenal chromaffin tumors.
Show evidence (1 reference)
PMID:11331613 SUPPORT In Vitro
"Mutations associated with the PHE-only phenotype (type 2C) promoted HIF-alpha ubiquitylation in vitro and demonstrated wild-type binding patterns with pVHL interacting proteins, suggesting that loss of other pVHL functions are necessary for PHE susceptibility."
A survey of 13 naturally occurring VHL mutations spanning the clinical subclasses found that the pheochromocytoma-only alleles retain, rather than lose, HIF-alpha regulation. That dissociation is the direct evidence for a HIF-independent arm.
Chromatin Remodeler Co-Driver Loss
PBRM1, BAP1 and SETD2 sit near VHL on chromosome 3p, so the loss of heterozygosity that supplies the somatic second hit typically removes them along with VHL. Their inactivation is a cooperating event in clear cell renal carcinoma rather than a consequence of pseudohypoxia, and which modifier is hit tracks with tumor behaviour: BAP1 loss with high-grade, sarcomatoid, poor-survival disease and PBRM1 loss with a more indolent course. This is a somatic co-driver layer observed mainly in sporadic clear cell renal carcinoma cohorts; inherited VHL-associated tumors carry fewer alterations overall, so the extent to which the same requirement holds in VHL disease is not settled.
chromatin remodeling GO:0006338 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology.
Downstream
Clear Cell Renal Cell Carcinoma Chromatin-modifier co-deletion accompanies VHL loss in most clear cell renal carcinomas and stratifies their grade and prognosis.
Show evidence (2 references)
PMID:39965361 SUPPORT Human Clinical
"The top 10 mutated genes were VHL (73.9%), PBRM1 (42.4%), SETD2 (25.3%), CDKN2A (20.0%), BAP1 (16.4%), CDKN2B (16.0%), KDM5C (14.5%), TP53 (12.9%), PTEN (11.7%), and TERT (9.2%)."
Quantifies the co-occurrence in 858 patients with metastatic clear cell renal carcinoma. Establishes that the chromatin modifiers are mutated alongside VHL at high frequency; it does not by itself establish that they are required.
PMID:41915349 SUPPORT Other
"PBRM1 loss (∼40%), a subunit of the SWI/SNF complex, is linked to a more indolent phenotype and potential sensitivity to antiangiogenic therapy as well as immune checkpoint inhibitor (ICI) resistance. SETD2 mutations (10–15%) cause genomic instability and are associated with aggressive features..."
Sources the claim that which chromatin modifier is lost defines distinct molecular subtypes with different grade, prognosis and therapy response.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Von Hippel-Lindau Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Cardiovascular 1
Retinal Hemangioblastoma FREQUENT Retinal capillary hemangioma HP:0009711 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal capillary hemangioma (HP:0009711). HP:0009711 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:892 SUPPORT Other
"HP:0009711 | Retinal capillary hemangioma | Frequent (79-30%)"
Orphanet lists retinal capillary hemangioma as a frequent VHL phenotype.
Digestive 1
Pancreatic Cysts FREQUENT HP:0001737 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pancreatic cysts (HP:0001737). HP:0001737 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37980175 SUPPORT Other
"Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament."
This review includes cysts and tumors of the pancreatobiliary system among VHL-associated lesions.
Ear 1
Endolymphatic sac tumor OCCASIONAL HP:0030393 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Endolymphatic sac tumor (HP:0030393). HP:0030393 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:892 SUPPORT Other
"HP:0030393 | Endolymphatic sac tumor | Occasional (29-5%)"
Orphanet lists endolymphatic sac tumor as an occasional VHL phenotype.
Endocrine 2
Pheochromocytoma FREQUENT HP:0002666 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pheochromocytoma (HP:0002666). HP:0002666 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:892 SUPPORT Other
"pheochromocytoma/paraganglioma."
The Orphanet definition includes pheochromocytoma/paraganglioma in the VHL neoplasm spectrum.
Pancreatic Neuroendocrine Tumor OCCASIONAL Pancreatic endocrine tumor HP:0030405 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pancreatic endocrine tumor (HP:0030405). HP:0030405 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:892 SUPPORT Other
"HP:0030405 | Pancreatic endocrine tumor | Occasional (29-5%)"
Orphanet lists pancreatic endocrine tumor as an occasional VHL phenotype.
Genitourinary 2
Clear Cell Renal Cell Carcinoma VERY_FREQUENT HP:0006770 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clear cell renal cell carcinoma (HP:0006770). HP:0006770 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34818478 SUPPORT
"Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α)."
Confirms high incidence of RCC in VHL disease due to VHL gene inactivation and constitutive HIF-2α activation.
Renal Cysts VERY_FREQUENT Multiple renal cysts HP:0005562 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Multiple renal cysts (HP:0005562). HP:0005562 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37980175 SUPPORT Other
"Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament."
This review includes kidney cysts and tumors among VHL-associated lesions.
Neoplasm 1
Cerebellar Hemangioblastoma FREQUENT HP:0006880 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar hemangioblastoma (HP:0006880). HP:0006880 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:892 SUPPORT Other
"HP:0006880 | Cerebellar hemangioblastoma | Frequent (79-30%)"
Orphanet lists cerebellar hemangioblastoma as a frequent VHL phenotype.
🧬

Genetic Associations

1
VHL (Germline Loss-of-Function Mutations)
Gene: VHL hgnc:12687 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is VHL (hgnc:12687). hgnc:12687 is a gene from the HUGO Gene Nomenclature Committee.
Autosomal Dominant
Show evidence (1 reference)
CGGV:assertion_30c04ced-b74d-465a-8d7d-eb822109b7f1-2020-05-14T004116.004Z SUPPORT Other
"VHL | HGNC:12687 | von Hippel-Lindau disease | MONDO:0008667 | AD | Definitive"
ClinGen classifies the VHL-von Hippel-Lindau disease gene-disease relationship as definitive with autosomal dominant inheritance.
💊

Medical Actions

4
Surveillance Protocol
Action: cancer screeningNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cancer screening (NCIT:C15406). NCIT:C15406 is a clinical intervention from the NCI Thesaurus. Ontology label: Cancer Screening NCIT:C15406
Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.
Nephron-Sparing Surgery
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.
Belzutifan
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: belzutifan NCIT:C135627 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses belzutifan (NCIT:C135627). NCIT:C135627 is a therapeutic agent from the NCI Thesaurus.
HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.
Show evidence (3 references)
PMID:34818478 SUPPORT
"Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease."
Phase 2 clinical trial demonstrates belzutifan efficacy and tolerability across VHL-associated tumor types.
PMID:38849055 SUPPORT Human Clinical
"All 16 eyes were graded as improved, with a response rate of 100.0% (95% confidence interval, 79.4%-100%)."
The ocular subgroup of LITESPARK-004 is the upper end of belzutifan's activity range across the VHL tumor spectrum, with every evaluable eye improving and no new retinal hemangioblastomas at a median 37 months.
PMID:41124218 SUPPORT Human Clinical
"the percentage of participants with a confirmed objective response was 26% (95% confidence interval [CI], 17 to 38) and the percentage of participants with disease control was 85% (95% CI, 74 to 92)."
The lower end of the same range. Phase 2 activity in 72 participants with advanced pheochromocytoma or paraganglioma extends HIF-2alpha inhibition to the chromaffin arm of the spectrum, while the response gap against ocular disease is what the belzutifan-response knowledge gap below is about.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.
🔬

Biochemical Markers

2
VHL Genetic Testing
Plasma Metanephrines
{ }

Source YAML

click to show 
name: Von Hippel-Lindau Disease
creation_date: '2026-01-26T02:55:13Z'
description: >-
  Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome
  caused by germline pathogenic variants in the VHL tumor suppressor gene. It is
  characterized by the development of highly vascularized tumors including clear cell
  renal cell carcinoma, hemangioblastomas of the CNS and retina, pheochromocytomas,
  and pancreatic neuroendocrine tumors. VHL disease exemplifies the two-hit hypothesis
  for tumor suppressor genes and the role of hypoxia signaling dysregulation in
  tumorigenesis through constitutive HIF activation.
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
parents:
- hereditary cancer-predisposing syndrome
has_subtypes:
- name: VHL Type 1
  description: >-
    Characterized by low risk of pheochromocytoma but high risk of renal cell carcinoma,
    hemangioblastomas, and pancreatic tumors. Associated with truncating mutations,
    large deletions, and missense mutations affecting HIF binding.
- name: VHL Type 2A
  description: >-
    Characterized by pheochromocytoma and hemangioblastomas but low risk of renal
    cell carcinoma. Associated with specific missense mutations.
- name: VHL Type 2B
  description: >-
    High risk of all VHL-associated tumors including pheochromocytoma, renal cell
    carcinoma, and hemangioblastomas. Associated with specific missense mutations.
- name: VHL Type 2C
  description: >-
    Pheochromocytoma only, without other VHL manifestations. Associated with specific
    missense mutations that retain some HIF regulatory function.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_vhl_hif_pseudohypoxia_tumor_model
  hypothesis_label: Canonical VHL Loss / HIF Pseudohypoxia / Vascular Tumor Predisposition Model
  status: CANONICAL
  description: >-
    Von Hippel-Lindau (VHL) disease is caused by germline heterozygous loss-of-function variants in VHL
    on 3p25.3. The VHL protein is the substrate recognition subunit of an E3 ubiquitin ligase complex
    that targets prolyl-hydroxylated HIF-1α/2α for degradation under normoxic conditions. Biallelic VHL
    inactivation ('second hit') in susceptible tissues stabilizes HIF-α despite normal oxygen levels — a
    'pseudohypoxic' state — and drives constitutive transcription of VEGF, PDGF, EPO, TGF-α, and other
    pro-angiogenic and growth-promoting factors. This produces the canonical VHL tumor spectrum: retinal
    and CNS hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma/paraganglioma,
    pancreatic neuroendocrine tumors, and endolymphatic sac tumors. The HIF-2α-selective inhibitor
    belzutifan (FDA-approved 2021) shrinks VHL-associated tumors, providing direct pharmacologic
    validation of the HIF-pseudohypoxia axis as the canonical pathogenic mechanism.
  notes: >-
    Retained as CANONICAL with four mandatory
    qualifier annotations. The 2026 openscientist hypothesis-search
    report
    (kb/hypotheses/Von_Hippel-Lindau_Disease/canonical_vhl_hif_pseudohypoxia_tumor_model)
    finds STRONGLY SUPPORTED across five convergent evidence
    layers: (1) Mendelian genetics with ~95% penetrance by age 60;
    (2) atomic-resolution VHL-hydroxyproline crystal structures
    defining the oxygen-sensing mechanism; (3) FDA-approved
    belzutifan (HIF-2α inhibitor) demonstrating durable tumor
    shrinkage across all VHL-associated tumor types;
    (4) acquired on-target resistance mutations in the HIF-2α
    gatekeeper pocket confirming core HIF-2 dependency;
    (5) GWAS identification of EPAS1/HIF-2α as a sporadic RCC
    susceptibility locus, linking hereditary and sporadic
    pathogenesis. Four mandatory qualifications: (1) HIF-2α (NOT
    HIF-1α) is the specific oncogenic isoform in ccRCC, while
    HIF-1α functions as a bona fide tumor suppressor on
    chromosome 14q; (2) type 2C VHL mutations cause
    pheochromocytoma DESPITE retaining normal HIF-α
    ubiquitylation, proving the existence of HIF-INDEPENDENT
    tumor-suppressor functions of pVHL; (3) VHL loss alone is
    necessary but INSUFFICIENT for ccRCC — cooperating mutations
    in 3p chromatin remodeling genes (PBRM1, BAP1, SETD2) are
    required co-drivers that define distinct molecular and
    prognostic subtypes; (4) the tissue specificity of VHL disease
    — why only certain organs develop tumors despite ubiquitous
    VHL expression — remains mechanistically unexplained.
    Belzutifan FDA approval (2021) provides the strongest
    pharmacologic validation of the HIF-pseudohypoxia axis.
  evidence:
  - reference: PMID:37980175
    reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "von Hippel-Lindau (VHL) disease is characterized by biallelic inactivation of the VHL gene leading to abnormal or absent VHL protein function, and constitutive activation of hypoxia-inducible factors (HIF) that leads to pro-tumorigenic sign"
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
  - reference: PMID:22037472
    reference_title: "Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In this article, we identify focal, homozygous deletions of the HIF1α locus on 14q in clear cell renal carcinoma cell lines. Wild-type HIF1α suppresses renal carcinoma growth, but the products of these altered loci do not."
    explanation: >-
      Backs qualifier 1 in the notes above. HIF-1α behaves as a
      kidney cancer suppressor rather than an oncogenic driver, so
      the oncogenic isoform in ccRCC is specifically HIF-2α and an
      undifferentiated reference to HIF-alpha stabilization is
      imprecise.
  - reference: PMID:36253570
    reference_title: "PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, loss of VHL alone is often insufficient to drive oncogenesis. Results from genomic studies have shown that co-deletions of VHL with one (or more) of three genes encoding proteins involved in chromatin modification and remodelling, polybromo-1 gene (PBRM1), BRCA1-associated protein 1 (BAP1) and SET domain-containing 2 (SETD2), are common and important co-drivers of tumorigenesis."
    explanation: >-
      Backs qualifier 3 in the notes above: VHL inactivation
      establishes pseudohypoxia but is often not sufficient on its
      own for clear cell renal carcinoma, which typically also
      carries a 3p chromatin-modifier co-deletion.
  - reference: PMID:21131975
    reference_title: "Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 × 10⁻⁸) and rs7579899 (P = 2.3 × 10⁻⁹), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC."
    explanation: >-
      Common variation at the EPAS1 (HIF-2α) locus is associated
      with sporadic renal cell carcinoma risk at genome-wide
      significance, connecting the hereditary VHL/HIF axis to
      population-level susceptibility.
pathophysiology:
- name: VHL Tumor Suppressor Loss
  conforms_to: "germline_two_hit_tumor_predisposition#Biallelic Tumor Suppressor Inactivation in a Susceptible Cell"
  description: >-
    Germline heterozygous VHL mutations result in one functional allele. Somatic
    loss or mutation of the remaining wild-type allele (second hit) eliminates VHL
    function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis
    for tumor suppressor gene inactivation.
  biological_processes:
  - preferred_term: cellular response to hypoxia
    modifier: ABNORMAL
    term:
      id: GO:0071456
      label: cellular response to hypoxia
  downstream:
  - target: Loss of HIF Degradation
    description: VHL loss prevents ubiquitination of HIF-alpha subunits
  - target: HIF-Independent pVHL Function Loss
    description: >-
      The same loss of pVHL also removes its HIF-independent activities, which is
      the arm that pheochromocytoma-only (type 2C) alleles implicate.
  - target: Chromatin Remodeler Co-Driver Loss
    description: >-
      The somatic second hit is usually loss of heterozygosity across the whole
      3p arm, which co-deletes the neighbouring chromatin modifiers along with VHL.
  evidence:
  - reference: PMID:37980175
    reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
    supports: SUPPORT
    snippet: "von Hippel-Lindau (VHL) disease is characterized by biallelic inactivation of the VHL gene leading to abnormal or absent VHL protein function, and constitutive activation of hypoxia-inducible factors (HIF) that leads to pro-tumorigenic signaling."
    explanation: Confirms that biallelic VHL inactivation (consistent with two-hit hypothesis) leads to constitutive HIF activation and pro-tumorigenic signaling.
- name: Loss of HIF Degradation
  description: >-
    VHL protein (pVHL) functions as the substrate recognition component of an E3
    ubiquitin ligase complex that targets hydroxylated HIF-alpha subunits for
    proteasomal degradation under normoxic conditions. Loss of VHL function prevents
    HIF-alpha degradation, allowing HIF accumulation even in the presence of oxygen.
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: DECREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  downstream:
  - target: Constitutive HIF Activation
    description: Stabilized HIF-alpha accumulates and activates target genes
  evidence:
  - reference: PMID:19671042
    reference_title: "The VHL tumor suppressor: master regulator of HIF."
    supports: SUPPORT
    snippet: "The von-Hippel Lindau tumor suppressor (pVHL) is the substrate recognition component of an E3 ubiquitin ligase and functions as a master regulator of HIF activity by targeting the hydroxylated HIF-alpha subunit for ubiquitylation and rapid proteasomal degradation under normoxic conditions."
    explanation: Defines pVHL as the substrate recognition component of an E3 ubiquitin ligase that targets hydroxylated HIF-alpha for proteasomal degradation.
  - reference: PMID:15162797
    reference_title: "von Hippel-Lindau tumor suppressor: not only HIF's executioner."
    supports: SUPPORT
    snippet: "VHL tumor suppressor is a specific substrate-recognition component of the E3 ubiquitin complex, which regulates proteasomal degradation of the subunit of the hypoxia inducible transcription factor (HIF). Impaired VHL complex function leads to accumulation of HIF, overexpression of various HIF-induced gene products and formation of highly vascular neoplasia."
    explanation: Confirms that impaired VHL function leads to HIF accumulation due to loss of proteasomal degradation.
  - reference: PMID:12050673
    reference_title: "Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The crystal structure of a hydroxylated HIF-1 alpha peptide bound to VCB (pVHL, elongins C and B) and solution binding assays reveal a single, conserved hydroxyproline-binding pocket in pVHL."
    explanation: >-
      Gives the step its structural basis: capture of HIF-alpha by pVHL runs
      through one conserved pocket that reads the hydroxyproline mark, which is
      what beta-domain VHL mutations disrupt.
- name: Constitutive HIF Activation
  description: >-
    Stabilized HIF-alpha (primarily HIF-2alpha in RCC) dimerizes with HIF-1beta
    (ARNT) and translocates to the nucleus where it activates transcription of
    hypoxia-responsive genes. This occurs constitutively regardless of oxygen
    levels, creating a pseudo-hypoxic state. The two alpha isoforms are not
    interchangeable here: HIF-2alpha is the oncogenic driver, and pharmacologic
    and genetic work in clear cell renal carcinoma places the tumor's dependency
    specifically on HIF-2 rather than on HIF-alpha generically.
  biological_processes:
  - preferred_term: response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0001666
      label: response to hypoxia
  downstream:
  - target: VEGF Overexpression and Angiogenesis
    description: HIF activates VEGF transcription driving neovascularization
  - target: Growth Factor and Metabolic Reprogramming
    description: HIF activates genes promoting proliferation and altered metabolism
  evidence:
  - reference: PMID:11114720
    reference_title: "Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1alpha and HIF-2alpha proteins under normoxic conditions."
    explanation: Demonstrates that VHL deficiency leads to constitutive HIF-alpha expression even under normoxic conditions, and that VHL restoration can reverse this effect.
  - reference: PMID:31727677
    reference_title: "HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2α, which interferes with drug binding and precluded HIF-2 complex dissociation."
    explanation: >-
      Resistance arising through a gatekeeper substitution in the drug-binding
      pocket of HIF-2alpha itself is on-target genetic evidence that the tumor
      depends on HIF-2 activity, which is why this node names HIF-2alpha rather
      than HIF-alpha generically. Indirect because the inference runs from an
      acquired drug-resistance allele back to the driver.
- name: VEGF Overexpression and Angiogenesis
  conforms_to: "tumor_angiogenesis#Angiogenic Switch and VEGF-Driven Neovascularization"
  description: >-
    VEGF (vascular endothelial growth factor) is a direct HIF target gene.
    Constitutive HIF activation leads to chronic VEGF overexpression, driving
    extensive tumor angiogenesis. This explains the highly vascular nature of
    VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.
  biological_processes:
  - preferred_term: vascular endothelial growth factor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0038084
      label: vascular endothelial growth factor signaling pathway
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  downstream:
  - target: Tumor Development
    description: Neovascularization supports tumor growth and progression
  evidence:
  - reference: PMID:11114720
    reference_title: "Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function."
    supports: SUPPORT
    snippet: "In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2alpha mRNA in stromal cells of the tumors."
    explanation: Demonstrates elevated VEGF levels in VHL-associated hemangioblastomas, linking HIF activation to VEGF overexpression.
  - reference: PMID:11114720
    reference_title: "Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function."
    supports: SUPPORT
    snippet: "The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1alpha and HIF-2alpha proteins."
    explanation: Confirms VHL protein regulates angiogenesis through HIF-mediated mechanisms.
  - reference: PMID:9787178
    reference_title: "Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surprisingly, we observed Epo mRNA expression in all hemangioblastoma specimens analyzed, but in none of four glioblastomas. In contrast, VEGF mRNA was expressed in all hemangioblastomas and all glioblastomas. In situ hybridization revealed neoplastic stromal cells as Epo- and VEGF-producing cells in hemangioblastomas."
    explanation: >-
      Locates the pseudohypoxic transcriptional output in the tumor cell itself.
      Two HIF target genes are co-expressed by the neoplastic stromal cells of
      all 11 hemangioblastomas examined, in a non-hypoxic microenvironment, and
      the EPO signal separates hemangioblastoma from glioblastoma. This is the
      erythropoietin arm of the hypothesis, which the entry otherwise asserted
      without a citation.
- name: Growth Factor and Metabolic Reprogramming
  description: >-
    HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1,
    and glycolytic enzymes. This promotes cell proliferation, survival, and a
    shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.
  biological_processes:
  - preferred_term: cellular glucose homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0001678
      label: intracellular glucose homeostasis
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Tumor Development
    description: Growth factors and metabolic changes drive tumorigenesis
  evidence:
  - reference: PMID:37980175
    reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
    supports: SUPPORT
    snippet: "immunohistochemical studies for markers such as paired box 8 (PAX-8), carbonic anhydrase 9 (CA9), and glucose transporter 1 (GLUT-1) have an important role in routine clinical practice and represent cost-effective diagnostic tools."
    explanation: The use of GLUT-1 as a diagnostic marker for VHL-associated tumors reflects HIF-induced metabolic reprogramming with increased glucose uptake.
- name: Tumor Development
  conforms_to: "germline_two_hit_tumor_predisposition#Early-Onset, Multifocal, and Bilateral Tumor Spectrum"
  description: >-
    The combination of increased angiogenesis, growth factor signaling, and
    metabolic reprogramming creates a permissive environment for tumor development.
    Different tissues show variable susceptibility, explaining the characteristic
    tumor spectrum of VHL disease including RCC, hemangioblastomas, and pheochromocytomas.
  downstream:
  - target: Clear Cell Renal Cell Carcinoma
    description: VHL loss and HIF activation predispose renal tubular epithelium to clear cell RCC.
    evidence:
    - reference: PMID:34818478
      reference_title: "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal
        cell carcinoma owing to VHL gene inactivation and constitutive activation of
        the transcription factor hypoxia-inducible factor 2α (HIF-2α).
      explanation: This links VHL/HIF activation to renal cell carcinoma in VHL disease.
  - target: Cerebellar Hemangioblastoma
    description: Highly vascular CNS hemangioblastomas are part of the VHL tumor spectrum.
    evidence:
    - reference: ORPHA:892
      reference_title: "Von Hippel-Lindau disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0006880 | Cerebellar hemangioblastoma | Frequent (79-30%)"
      explanation: Orphanet lists cerebellar hemangioblastoma as a frequent VHL phenotype.
  - target: Retinal Hemangioblastoma
    description: Retinal capillary hemangioblastomas are part of the VHL vascular tumor spectrum.
    evidence:
    - reference: ORPHA:892
      reference_title: "Von Hippel-Lindau disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0009711 | Retinal capillary hemangioma | Frequent (79-30%)"
      explanation: Orphanet lists retinal capillary hemangioma as a frequent VHL phenotype.
  - target: Pheochromocytoma
    description: VHL-associated tumor susceptibility includes adrenal and extra-adrenal chromaffin tumors.
    evidence:
    - reference: ORPHA:892
      reference_title: "Von Hippel-Lindau disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "pheochromocytoma/paraganglioma."
      explanation: The Orphanet definition includes pheochromocytoma/paraganglioma in the VHL neoplasm spectrum.
  - target: Pancreatic Neuroendocrine Tumor
    description: VHL tumor susceptibility includes pancreatic endocrine/neuroendocrine tumors.
    evidence:
    - reference: ORPHA:892
      reference_title: "Von Hippel-Lindau disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0030405 | Pancreatic endocrine tumor | Occasional (29-5%)"
      explanation: Orphanet lists pancreatic endocrine tumor as an occasional VHL phenotype.
  - target: Renal Cysts
    description: VHL-associated renal lesions include cystic kidney disease.
    evidence:
    - reference: PMID:37980175
      reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament.
      explanation: This review includes kidney cysts and tumors among VHL-associated lesions.
  - target: Pancreatic Cysts
    description: VHL-associated pancreatobiliary lesions include pancreatic cystic disease.
    evidence:
    - reference: PMID:37980175
      reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament.
      explanation: This review includes cysts and tumors of the pancreatobiliary system among VHL-associated lesions.
  - target: Endolymphatic sac tumor
    description: VHL tumor susceptibility can involve the endolymphatic sac of the inner ear.
    evidence:
    - reference: ORPHA:892
      reference_title: "Von Hippel-Lindau disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0030393 | Endolymphatic sac tumor | Occasional (29-5%)"
      explanation: Orphanet lists endolymphatic sac tumor as an occasional VHL phenotype.
  evidence:
  - reference: PMID:19671042
    reference_title: "The VHL tumor suppressor: master regulator of HIF."
    supports: SUPPORT
    snippet: "Mutations in pVHL can be found in familial and sporadic hemangioblastomas, clear cell carcinomas of the kidney, pheochromocytomas and inherited forms of erythrocytosis, illustrating the importance of disrupted molecular oxygen sensing in the pathogenesis of these diseases."
    explanation: Documents the characteristic tumor spectrum of VHL disease and links it to disrupted oxygen sensing.
  - reference: PMID:15162797
    reference_title: "von Hippel-Lindau tumor suppressor: not only HIF's executioner."
    supports: SUPPORT
    snippet: "Loss of von Hippel-Lindau (VHL) protein function results in an autosomal-dominant cancer syndrome known as VHL disease, which manifests as angiomas of the retina, hemangioblastomas of the central nervous system, renal clear-cell carcinomas and pheochromocytomas."
    explanation: Confirms the characteristic tumor spectrum associated with VHL protein loss.
- name: HIF-Independent pVHL Function Loss
  biological_scale: MOLECULAR
  description: >-
    pVHL has activities beyond HIF-alpha ubiquitylation, including fibronectin
    and extracellular matrix assembly, primary cilium maintenance, and
    regulation of JAK/STAT signalling through SOCS proteins. Loss of these
    activities is a separate arm of VHL pathogenesis from pseudohypoxia. The
    evidence that it matters clinically comes from the genotype-phenotype
    boundary: the alleles that produce pheochromocytoma without hemangioblastoma
    or renal carcinoma (type 2C) still ubiquitylate HIF-alpha normally and still
    bind pVHL partners normally, so something other than HIF dysregulation must
    be driving chromaffin-cell transformation in those families. Which pVHL
    activity that is has not been established.
  downstream:
  - target: Pheochromocytoma
    description: >-
      The arm of VHL pathogenesis that type 2C alleles implicate in adrenal and
      extra-adrenal chromaffin tumors.
  evidence:
  - reference: PMID:11331613
    reference_title: "Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mutations associated with the PHE-only phenotype (type 2C) promoted HIF-alpha ubiquitylation in vitro and demonstrated wild-type binding patterns with pVHL interacting proteins, suggesting that loss of other pVHL functions are necessary for PHE susceptibility."
    explanation: >-
      A survey of 13 naturally occurring VHL mutations spanning the clinical
      subclasses found that the pheochromocytoma-only alleles retain, rather than
      lose, HIF-alpha regulation. That dissociation is the direct evidence for a
      HIF-independent arm.
- name: Chromatin Remodeler Co-Driver Loss
  biological_scale: MOLECULAR
  description: >-
    PBRM1, BAP1 and SETD2 sit near VHL on chromosome 3p, so the loss of
    heterozygosity that supplies the somatic second hit typically removes them
    along with VHL. Their inactivation is a cooperating event in clear cell renal
    carcinoma rather than a consequence of pseudohypoxia, and which modifier is
    hit tracks with tumor behaviour: BAP1 loss with high-grade, sarcomatoid,
    poor-survival disease and PBRM1 loss with a more indolent course. This is a
    somatic co-driver layer observed mainly in sporadic clear cell renal
    carcinoma cohorts; inherited VHL-associated tumors carry fewer alterations
    overall, so the extent to which the same requirement holds in VHL disease is
    not settled.
  biological_processes:
  - preferred_term: chromatin remodeling
    modifier: DECREASED
    term:
      id: GO:0006338
      label: chromatin remodeling
  downstream:
  - target: Clear Cell Renal Cell Carcinoma
    description: >-
      Chromatin-modifier co-deletion accompanies VHL loss in most clear cell
      renal carcinomas and stratifies their grade and prognosis.
  evidence:
  - reference: PMID:39965361
    reference_title: "The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The top 10 mutated genes were VHL (73.9%), PBRM1 (42.4%), SETD2 (25.3%), CDKN2A (20.0%), BAP1 (16.4%), CDKN2B (16.0%), KDM5C (14.5%), TP53 (12.9%), PTEN (11.7%), and TERT (9.2%)."
    explanation: >-
      Quantifies the co-occurrence in 858 patients with metastatic clear cell
      renal carcinoma. Establishes that the chromatin modifiers are mutated
      alongside VHL at high frequency; it does not by itself establish that they
      are required.
  - reference: PMID:41915349
    reference_title: "Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PBRM1 loss (∼40%), a subunit of the SWI/SNF complex, is linked to a more indolent phenotype and potential sensitivity to antiangiogenic therapy as well as immune checkpoint inhibitor (ICI) resistance. SETD2 mutations (10–15%) cause genomic instability and are associated with aggressive features but may improve the ICI response. BAP1 mutation (10–15%) strongly predicts high-grade tumors, sarcomatoid differentiation, poor survival, and therapy resistance."
    explanation: >-
      Sources the claim that which chromatin modifier is lost defines distinct
      molecular subtypes with different grade, prognosis and therapy response.
phenotypes:
- category: Neoplastic
  name: Clear Cell Renal Cell Carcinoma
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Clear cell RCC occurs in approximately 70% of VHL patients. Tumors are often
    bilateral and multifocal. Mean age of diagnosis is 39 years, compared to 62
    years for sporadic RCC. Leading cause of mortality in VHL patients.
  phenotype_term:
    preferred_term: Clear cell renal cell carcinoma
    term:
      id: HP:0006770
      label: Clear cell renal cell carcinoma
  evidence:
  - reference: PMID:34818478
    reference_title: "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease."
    supports: SUPPORT
    snippet: >-
      Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal
      cell carcinoma owing to VHL gene inactivation and constitutive activation of
      the transcription factor hypoxia-inducible factor 2α (HIF-2α).
    explanation: >-
      Confirms high incidence of RCC in VHL disease due to VHL gene inactivation
      and constitutive HIF-2α activation.
- category: Neoplastic
  name: Cerebellar Hemangioblastoma
  frequency: FREQUENT
  diagnostic: true
  description: >-
    Hemangioblastomas of the cerebellum are the most common CNS manifestation,
    occurring in 60-80% of VHL patients. These highly vascular tumors may cause
    symptoms through mass effect or associated cyst formation.
  phenotype_term:
    preferred_term: Cerebellar hemangioblastoma
    term:
      id: HP:0006880
      label: Cerebellar hemangioblastoma
  evidence:
  - reference: ORPHA:892
    reference_title: "Von Hippel-Lindau disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0006880 | Cerebellar hemangioblastoma | Frequent (79-30%)"
    explanation: Orphanet lists cerebellar hemangioblastoma as a frequent VHL phenotype.
- category: Neoplastic
  name: Retinal Hemangioblastoma
  frequency: FREQUENT
  diagnostic: true
  description: >-
    Retinal hemangioblastomas (also called retinal capillary hemangiomas) occur in
    25-60% of VHL patients and may be the presenting manifestation. They can cause
    vision loss through exudation, hemorrhage, or retinal detachment.
  phenotype_term:
    preferred_term: Retinal capillary hemangioma
    term:
      id: HP:0009711
      label: Retinal capillary hemangioma
  evidence:
  - reference: ORPHA:892
    reference_title: "Von Hippel-Lindau disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009711 | Retinal capillary hemangioma | Frequent (79-30%)"
    explanation: Orphanet lists retinal capillary hemangioma as a frequent VHL phenotype.
- category: Neoplastic
  name: Pheochromocytoma
  frequency: FREQUENT
  description: >-
    Pheochromocytomas occur in 10-20% of VHL patients overall but are more common
    in Type 2 families (up to 60%). Often bilateral and may occur at young ages.
    Screening by plasma or urine metanephrines is recommended.
  phenotype_term:
    preferred_term: Pheochromocytoma
    term:
      id: HP:0002666
      label: Pheochromocytoma
  evidence:
  - reference: ORPHA:892
    reference_title: "Von Hippel-Lindau disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "pheochromocytoma/paraganglioma."
    explanation: The Orphanet definition includes pheochromocytoma/paraganglioma in the VHL neoplasm spectrum.
- category: Neoplastic
  name: Pancreatic Neuroendocrine Tumor
  frequency: OCCASIONAL
  description: >-
    Pancreatic neuroendocrine tumors occur in 5-17% of VHL patients. Most are
    nonfunctional. The main concern is metastatic potential, though most are
    indolent. Size-based surveillance guides management.
  phenotype_term:
    preferred_term: Pancreatic endocrine tumor
    term:
      id: HP:0030405
      label: Pancreatic endocrine tumor
  evidence:
  - reference: ORPHA:892
    reference_title: "Von Hippel-Lindau disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030405 | Pancreatic endocrine tumor | Occasional (29-5%)"
    explanation: Orphanet lists pancreatic endocrine tumor as an occasional VHL phenotype.
- category: Renal
  name: Renal Cysts
  frequency: VERY_FREQUENT
  description: >-
    Multiple renal cysts are common in VHL patients and may precede RCC development.
    Some cysts contain foci of clear cell RCC. Surveillance imaging monitors for
    solid enhancing components.
  phenotype_term:
    preferred_term: Multiple renal cysts
    term:
      id: HP:0005562
      label: Multiple renal cysts
  evidence:
  - reference: PMID:37980175
    reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament.
    explanation: This review includes kidney cysts and tumors among VHL-associated lesions.
- category: Pancreatic
  name: Pancreatic Cysts
  frequency: FREQUENT
  description: >-
    Pancreatic cysts (serous cystadenomas) are common in VHL patients but are
    almost always benign. They are distinct from pancreatic neuroendocrine tumors.
  phenotype_term:
    preferred_term: Pancreatic cysts
    term:
      id: HP:0001737
      label: Pancreatic cysts
  evidence:
  - reference: PMID:37980175
    reference_title: "von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individuals with VHL disease develop numerous cysts and tumors involving multiple organs including the kidneys, central nervous system, endolymphatic sac, lungs, pancreatobiliary system, adrenal glands, epididymis, and/or broad ligament.
    explanation: This review includes cysts and tumors of the pancreatobiliary system among VHL-associated lesions.
- category: Neoplastic
  name: Endolymphatic sac tumor
  frequency: OCCASIONAL
  description: >-
    Endolymphatic sac tumors are inner-ear neoplasms within the VHL tumor spectrum.
  phenotype_term:
    preferred_term: Endolymphatic sac tumor
    term:
      id: HP:0030393
      label: Endolymphatic sac tumor
  evidence:
  - reference: ORPHA:892
    reference_title: "Von Hippel-Lindau disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030393 | Endolymphatic sac tumor | Occasional (29-5%)"
    explanation: Orphanet lists endolymphatic sac tumor as an occasional VHL phenotype.
biochemical:
- name: VHL Genetic Testing
  notes: >-
    Molecular testing identifies germline VHL mutations in >99% of families meeting
    clinical criteria. Mutations include missense variants, truncating mutations,
    large deletions (detectable by MLPA), and deep intronic variants. Genotype-phenotype
    correlations guide surveillance: Type 1 mutations (truncating) have
    low pheochromocytoma risk; Type 2 mutations (missense) have higher risk.
- name: Plasma Metanephrines
  notes: >-
    Annual screening for pheochromocytoma using plasma fractionated metanephrines
    or 24-hour urine catecholamines and metanephrines. Essential for early detection
    of pheochromocytoma before hypertensive crises.
genetic:
- name: VHL
  gene_term:
    preferred_term: VHL
    term:
      id: hgnc:12687
      label: VHL
  association: Germline Loss-of-Function Mutations
  evidence:
  - reference: CGGV:assertion_30c04ced-b74d-465a-8d7d-eb822109b7f1-2020-05-14T004116.004Z
    reference_title: "VHL / von Hippel-Lindau disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "VHL | HGNC:12687 | von Hippel-Lindau disease | MONDO:0008667 | AD | Definitive"
    explanation: ClinGen classifies the VHL-von Hippel-Lindau disease gene-disease relationship as definitive with autosomal dominant inheritance.
  inheritance:
  - name: Autosomal Dominant
  notes: >-
    VHL (3p25.3) encodes the VHL protein, a substrate recognition subunit of an
    E3 ubiquitin ligase complex that targets HIF-alpha for degradation. Germline
    mutations include missense (particularly in Type 2), nonsense, frameshift,
    splice site, and large deletions. De novo mutations account for approximately
    20% of cases. Penetrance is nearly complete by age 65.
treatments:
- name: Surveillance Protocol
  description: >-
    Comprehensive surveillance beginning in childhood includes annual ophthalmologic
    examination (from age 1), annual plasma metanephrines (from age 5), annual
    abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from
    age 11). Earlier imaging if symptoms occur.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: NCIT:C15406
      label: Cancer Screening
- name: Nephron-Sparing Surgery
  description: >-
    Partial nephrectomy is the preferred approach for renal tumors to preserve
    renal function given the high likelihood of bilateral/multifocal disease.
    Surgery is typically recommended when tumors reach 3 cm to balance cancer
    risk with nephron preservation.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
- name: Belzutifan
  description: >-
    HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas,
    and pancreatic neuroendocrine tumors not requiring immediate surgery. First
    targeted therapy directly addressing the molecular defect in VHL disease.
    Objective response rates of 49% in RCC and 30-77% across tumor types.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: belzutifan
      term:
        id: NCIT:C135627
        label: Belzutifan
  evidence:
  - reference: PMID:34818478
    reference_title: "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease."
    supports: SUPPORT
    snippet: >-
      Belzutifan was associated with predominantly grade 1 and 2 adverse events and
      showed activity in patients with renal cell carcinomas and non-renal cell carcinoma
      neoplasms associated with VHL disease.
    explanation: >-
      Phase 2 clinical trial demonstrates belzutifan efficacy and tolerability
      across VHL-associated tumor types.
  - reference: PMID:38849055
    reference_title: "Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All 16 eyes were graded as improved, with a response rate of 100.0% (95% confidence interval, 79.4%-100%)."
    explanation: >-
      The ocular subgroup of LITESPARK-004 is the upper end of belzutifan's
      activity range across the VHL tumor spectrum, with every evaluable eye
      improving and no new retinal hemangioblastomas at a median 37 months.
  - reference: PMID:41124218
    reference_title: "Belzutifan for Advanced Pheochromocytoma or Paraganglioma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the percentage of participants with a confirmed objective response was 26% (95% confidence interval [CI], 17 to 38) and the percentage of participants with disease control was 85% (95% CI, 74 to 92)."
    explanation: >-
      The lower end of the same range. Phase 2 activity in 72 participants with
      advanced pheochromocytoma or paraganglioma extends HIF-2alpha inhibition to
      the chromaffin arm of the spectrum, while the response gap against ocular
      disease is what the belzutifan-response knowledge gap below is about.
- name: Genetic Counseling
  description: >-
    Genetic counseling and testing for at-risk family members. Children of affected
    parents have 50% risk. Predictive testing allows targeted surveillance in
    mutation carriers and can reassure non-carriers. Prenatal and preimplantation
    genetic testing are options.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
disease_term:
  preferred_term: von Hippel-Lindau disease
  term:
    id: MONDO:0008667
    label: von Hippel-Lindau disease
discussions:
- discussion_id: vhl_tissue_tropism_unexplained
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why do only retina, CNS, kidney, adrenal medulla, pancreas and endolymphatic
    sac form tumors after biallelic VHL loss, when VHL is expressed and lost in
    every tissue?
  attaches_to:
  - pathophysiology#Tumor Development
  rationale: >-
    This entry's causal chain runs from VHL loss through pseudohypoxia to a
    permissive growth environment and then simply asserts that "different tissues
    show variable susceptibility". That sentence is the gap, not an explanation
    of it. Nothing in the chain predicts which organs are at risk, and the
    somatic second hit is not obviously restricted to those organs, so tissue
    tropism has to come from a cofactor the model does not name. Candidates that
    have been raised include lineage-restricted enhancer accessibility at
    HIF-2alpha target loci, a developmentally arrested precursor population that
    persists only at certain sites, and tissue-specific tolerance thresholds for
    HIF-2alpha output. Resolving it matters clinically because surveillance
    protocols are currently organ lists derived from observed incidence rather
    than from mechanism.
  proposed_experiments:
  - experiment_id: vhl_single_cell_susceptible_vs_resistant_tissue
    name: Single-cell multi-omic comparison of VHL-susceptible and VHL-resistant tissues
    description: >-
      Paired single-cell RNA-seq and ATAC-seq on tissues that do and do not form
      VHL tumors (kidney proximal tubule, retinal progenitors, cerebellar
      molecular layer, adrenal medulla versus hepatocytes and skin fibroblasts),
      from VHL patients and controls, stratified by VHL genotype class.
    would_support:
    - pathophysiology#Tumor Development
    supporting_outcome:
    - >-
        Susceptible tissues show open, HIF-2alpha-responsive enhancer landscapes
        and higher HIF-2alpha target expression per unit of HIF-2alpha protein than
        resistant tissues do, identifying a chromatin-level cofactor that
        co-segregates with the observed organ list.
    refuting_outcome:
    - >-
        Enhancer accessibility and HIF-2alpha target output are comparable in
        susceptible and resistant tissues, which would move the explanation away
        from transcriptional competence toward cell-of-origin availability or
        differential rates of the somatic second hit.
- discussion_id: vhl_type2c_hif_independent_effector_unknown
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which pVHL activity, other than HIF-alpha ubiquitylation, is lost in type 2C
    mutants and drives chromaffin cell transformation?
  attaches_to:
  - pathophysiology#HIF-Independent pVHL Function Loss
  - has_subtypes#VHL Type 2C
  rationale: >-
    The dissociation is established: pheochromocytoma-only alleles ubiquitylate
    HIF-alpha normally and bind pVHL partners normally, yet still cause disease.
    What is missing is the effector. Fibronectin and extracellular matrix
    assembly, primary cilium maintenance, apoptosis and senescence control, and
    SOCS-mediated JAK regulation have all been proposed as HIF-independent pVHL
    functions, but no cited study isolates one of them as the type 2C lesion.
    Until that is settled, the pheochromocytoma arm of this entry rests on a node
    defined by what it is not. A quantitative interactome comparison of wild-type
    against type 1, type 2B and type 2C pVHL in chromaffin-lineage cells is the
    obvious discriminating experiment, followed by knockout of any partner lost
    selectively by type 2C mutants.
  evidence:
  - reference: PMID:11331613
    reference_title: "Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mutations associated with the PHE-only phenotype (type 2C) promoted HIF-alpha ubiquitylation in vitro and demonstrated wild-type binding patterns with pVHL interacting proteins, suggesting that loss of other pVHL functions are necessary for PHE susceptibility."
    explanation: >-
      Establishes the dissociation that creates the gap, and shows that the type
      2C alleles were not distinguishable from wild type on the interactor panel
      tested, so the responsible partner was not among them.
- discussion_id: vhl_mouse_models_miss_human_tumor_spectrum
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Conditional Vhl knockout mice reproduce HIF-driven vascular lesions but not
    retinal or cerebellar hemangioblastoma or clear cell renal carcinoma, so how
    much of the mechanism inferred from those models transfers to human VHL
    disease?
  attaches_to:
  - pathophysiology#Tumor Development
  - phenotypes#Retinal Hemangioblastoma
  rationale: >-
    Much of what is asserted about tumor initiation downstream of VHL loss comes
    from mouse conditional knockouts, and those models do not develop the human
    disease's defining lesions. No published model develops retinal
    hemangioblastoma, which is the most common clinical manifestation in
    patients. The mouse lesions that do appear are largely hepatic hemangiomas,
    a site VHL patients rarely present with. So the model system that supplies
    the mechanistic detail is not the model system that reproduces the disease,
    and mechanisms read off those mice describe what losing Vhl can do in mouse
    tissue rather than what is happening in a patient's retina or kidney. This
    sits directly underneath the tissue-tropism gap above: whatever explains why
    only some human organs are susceptible may also explain why mouse organs are
    susceptible in a different pattern.
  evidence:
  - reference: PMID:22763871
    reference_title: "Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These models, despite advancing our understanding the molecular role of VHL, are by and large unable to recapitulate the more common features of human VHL disease. Up to date, no model exists that develop retinal hemangioblastomas, the most common clinical manifestation."
    explanation: >-
      A review of fifteen years of Vhl-inactivation models stating that they do
      not reproduce the common human manifestations, and that no model develops
      retinal hemangioblastoma.
- discussion_id: vhl_belzutifan_response_determinants
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What molecular features determine why belzutifan clears every evaluable
    retinal hemangioblastoma but produces an objective response in roughly a
    quarter of advanced pheochromocytomas and paragangliomas?
  attaches_to:
  - treatments#Belzutifan
  rationale: >-
    The spread in response rate across tumor types is large enough that it is
    unlikely to be tissue accessibility alone, and it is the practical question
    for anyone deciding whether to offer belzutifan instead of surgery for a
    given lesion. Two determinants of resistance are established, both at the
    level of HIF-2alpha itself: an acquired gatekeeper substitution in the
    drug-binding pocket, and a SOCS3/JAK1/STAT3 enhancer circuit that raises
    EPAS1 transcription and so can outrun a drug that acts on the protein. What
    is not established is whether either predicts response prospectively, or
    whether the cross-tissue gradient instead tracks HIF-2alpha dependency,
    14q/HIF1A status, or chromatin-modifier genotype. Pre-treatment biopsy
    profiling across tumor types and VHL genotype classes, correlated with
    response, is the study that would settle it.
  evidence:
  - reference: PMID:31727677
    reference_title: "HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2α, which interferes with drug binding and precluded HIF-2 complex dissociation."
    explanation: >-
      One established resistance route, at the drug-binding pocket itself, found
      in patients on prolonged HIF-2 inhibitor therapy.
  - reference: PMID:41874563
    reference_title: "Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using a genome-wide CRISPR screen in von Hippel-Lindau-deficient (VHL-deficient) ccRCC cells, we identified SOCS3 as a key negative regulator of HIF-2α."
    explanation: >-
      A second, transcriptional route to sustained HIF-2alpha that acts upstream
      of the protein the drug binds. Cell-line and xenograft work in
      VHL-deficient clear cell renal carcinoma; not yet tested in patients
      progressing on belzutifan.
references:
- reference: DOI:10.1007/s11060-024-04676-5
  title: Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome.
    supporting_text: Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome.
    evidence:
    - reference: DOI:10.1007/s11060-024-04676-5
      reference_title: Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.1038/s41598-021-94132-5
  title: VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC).
    supporting_text: Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC).
    evidence:
    - reference: DOI:10.1038/s41598-021-94132-5
      reference_title: VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC).
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.1158/1078-0432.ccr-23-2592
  title: 'Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study'
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: 'Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study'
    supporting_text: 'Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment.'
    evidence:
    - reference: DOI:10.1158/1078-0432.ccr-23-2592
      reference_title: 'Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment.'
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.1158/1078-0432.ccr-24-3525
  title: Update on Surveillance in Von Hippel–Lindau Disease
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs.
    supporting_text: Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs.
    evidence:
    - reference: DOI:10.1158/1078-0432.ccr-24-3525
      reference_title: Update on Surveillance in Von Hippel–Lindau Disease
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.1172/jci162480
  title: 'Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer'
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: 'Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer'
    supporting_text: 'Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer'
- reference: DOI:10.1172/jci175703
  title: Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
    supporting_text: Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
- reference: DOI:10.1186/s13023-024-03060-w
  title: Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited.
    supporting_text: To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited.
    evidence:
    - reference: DOI:10.1186/s13023-024-03060-w
      reference_title: Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.1186/s43042-024-00506-5
  title: Germline variants in the Von Hippel-Lindau tumor suppressor gene in Cuban patients
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms.
    supporting_text: Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms.
    evidence:
    - reference: DOI:10.1186/s43042-024-00506-5
      reference_title: Germline variants in the Von Hippel-Lindau tumor suppressor gene in Cuban patients
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.15586/jkcvhl.v11i4.324
  title: Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel–Lindau?
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems.
    supporting_text: Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems.
    evidence:
    - reference: DOI:10.15586/jkcvhl.v11i4.324
      reference_title: Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel–Lindau?
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.15586/jkcvhl.v11i4.362
  title: 'Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany'
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity.
    supporting_text: Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity.
    evidence:
    - reference: DOI:10.15586/jkcvhl.v11i4.362
      reference_title: 'Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.3390/cancers15061657
  title: Unique Characteristics of Patients with Von Hippel–Lindau Disease Defined by Various Diagnostic Criteria
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Unique Characteristics of Patients with Von Hippel–Lindau Disease Defined by Various Diagnostic Criteria
    supporting_text: 'Von Hippel–Lindau (VHL) disease diagnosis is based on two criteria sets: International criteria (IC, two hemangioblastomas, one hemangioblastoma plus one visceral lesion, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion); or Danish criteria (DC, two clinical manifestations, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion).'
    evidence:
    - reference: DOI:10.3390/cancers15061657
      reference_title: Unique Characteristics of Patients with Von Hippel–Lindau Disease Defined by Various Diagnostic Criteria
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Von Hippel–Lindau (VHL) disease diagnosis is based on two criteria sets: International criteria (IC, two hemangioblastomas, one hemangioblastoma plus one visceral lesion, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion); or Danish criteria (DC, two clinical manifestations, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion).'
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.3390/diagnostics14171909
  title: Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body.
    supporting_text: This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body.
    evidence:
    - reference: DOI:10.3390/diagnostics14171909
      reference_title: Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics
      supports: SUPPORT
      evidence_source: OTHER
      snippet: This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
- reference: DOI:10.7554/elife.80774
  title: Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
  found_in:
  - Von_Hippel-Lindau_Disease-deep-research-falcon.md
  findings:
  - statement: Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
    supporting_text: von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that binds to the three hypoxia-inducible factor alpha subunits (HIF1-3α) for polyubiquitylation under conditions of normoxia, targeting them for immediate degradation by the proteasome.
    evidence:
    - reference: DOI:10.7554/elife.80774
      reference_title: Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that binds to the three hypoxia-inducible factor alpha subunits (HIF1-3α) for polyubiquitylation under conditions of normoxia, targeting them for immediate degradation by the proteasome.
      explanation: Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
📚

References & Deep Research

References

13
DOI:10.1007/s11060-024-04676-5
Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease
1 finding
Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome.
"Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome."
Show evidence (1 reference)
DOI:10.1007/s11060-024-04676-5 SUPPORT Human Clinical
"Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.1038/s41598-021-94132-5
VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
1 finding
Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC).
"Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC)."
Show evidence (1 reference)
DOI:10.1038/s41598-021-94132-5 SUPPORT Human Clinical
"Inactivation of the tumor suppressor von Hippel–Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC)."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.1158/1078-0432.ccr-23-2592
Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
1 finding
Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
"Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment."
Show evidence (1 reference)
DOI:10.1158/1078-0432.ccr-23-2592 SUPPORT Human Clinical
"Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.1158/1078-0432.ccr-24-3525
Update on Surveillance in Von Hippel–Lindau Disease
1 finding
Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs.
"Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs."
Show evidence (1 reference)
DOI:10.1158/1078-0432.ccr-24-3525 SUPPORT Other
"Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.1172/jci162480
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
1 finding
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
"Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer"
DOI:10.1172/jci175703
Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
1 finding
Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
"Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis"
DOI:10.1186/s13023-024-03060-w
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
1 finding
To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited.
"To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited."
Show evidence (1 reference)
DOI:10.1186/s13023-024-03060-w SUPPORT Human Clinical
"To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.1186/s43042-024-00506-5
Germline variants in the Von Hippel-Lindau tumor suppressor gene in Cuban patients
1 finding
Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms.
"Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms."
Show evidence (1 reference)
DOI:10.1186/s43042-024-00506-5 SUPPORT Human Clinical
"Von Hippel-Lindau (VHL) syndrome is an autosomal dominantly inherited disorder that predisposes to multiple neoplasms."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.15586/jkcvhl.v11i4.324
Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel–Lindau?
1 finding
Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems.
"Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems."
Show evidence (1 reference)
DOI:10.15586/jkcvhl.v11i4.324 SUPPORT Human Clinical
"Von Hippel–Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.15586/jkcvhl.v11i4.362
Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany
1 finding
Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity.
"Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity."
Show evidence (1 reference)
DOI:10.15586/jkcvhl.v11i4.362 SUPPORT Human Clinical
"Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.3390/cancers15061657
Unique Characteristics of Patients with Von Hippel–Lindau Disease Defined by Various Diagnostic Criteria
1 finding
Unique Characteristics of Patients with Von Hippel–Lindau Disease Defined by Various Diagnostic Criteria
"Von Hippel–Lindau (VHL) disease diagnosis is based on two criteria sets: International criteria (IC, two hemangioblastomas, one hemangioblastoma plus one visceral lesion, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion); or Danish criteria (DC, two clinical..."
Show evidence (1 reference)
DOI:10.3390/cancers15061657 SUPPORT Human Clinical
"Von Hippel–Lindau (VHL) disease diagnosis is based on two criteria sets: International criteria (IC, two hemangioblastomas, one hemangioblastoma plus one visceral lesion, or VHL family history/pathogenic variant plus hemangioblastoma/visceral lesion); or Danish criteria (DC, two clinical..."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.3390/diagnostics14171909
Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics
1 finding
This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body.
"This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body."
Show evidence (1 reference)
DOI:10.3390/diagnostics14171909 SUPPORT Other
"This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.
DOI:10.7554/elife.80774
Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
1 finding
Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
"von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that..."
Show evidence (1 reference)
DOI:10.7554/elife.80774 SUPPORT Human Clinical
"von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that..."
Deep research cited this publication as relevant literature for Von Hippel-Lindau Disease.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸
1. Disease Information
Edison Scientific Literature 36 citations 2026-04-05T23:24:59.252007

1. Disease Information

1.1 Definition/overview

VHL disease is a rare, inherited tumor predisposition syndrome characterized by development of benign and malignant tumors and cysts across multiple organs (CNS, retina, kidneys, pancreas, adrenals, and others). (gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2)

1.2 Key identifiers (as explicitly available in retrieved sources)

  • OMIM (disease): Von Hippel-Lindau syndrome OMIM #193300 (alvarez2024germlinevariantsin pages 1-2)
  • OMIM (gene): VHL tumor suppressor gene OMIM *608537 (alvarez2024germlinevariantsin pages 1-2)
  • ICD-10: Q85.83 (as used to define a cohort in a TriNetX real-world analysis) (hochberg2024isthetrinetx pages 1-2)

Not available from the retrieved evidence excerpts: Orphanet ORPHA code, MeSH unique ID, MONDO ID, ICD-11 code. These would normally be sourced from Orphanet/MeSH/MONDO directly, but they were not present in the accessible text segments used here (alvarez2024germlinevariantsin pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 1-2, hochberg2024isthetrinetx pages 1-2).

1.3 Synonyms/alternative names

Explicitly used name variants in retrieved sources include: - “Von Hippel–Lindau disease” / “von Hippel–Lindau (VHL) disease” / “VHL disease” / “VHL” (gomezvirgilio2024geneticspathophysiologyand pages 1-2) - “Von Hippel-Lindau syndrome” / “VHL syndrome” (alvarez2024germlinevariantsin pages 1-2) - “Von Hippel–Lindau (vHL) disease” / “vHL” (hochberg2024isthetrinetx pages 1-2)

1.4 Evidence provenance

The report synthesizes aggregated disease-level reviews (e.g., 2024 Diagnostics review; 2022 JCI review) and primary/real-world studies (claims-based epidemiology; clinical trial report; cohort analyses). (jonasch2024epidemiologyandeconomic pages 1-2, else2024belzutifanforvon pages 5-6, gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2, zhang2024vonhippellindau pages 1-2)

2. Etiology

2.1 Disease causal factors

  • Primary cause: Germline pathogenic variants in VHL, consistent with autosomal-dominant tumor predisposition; pVHL is a tumor suppressor that regulates HIFα stability via a Cullin2-based E3 ubiquitin ligase complex. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2)
  • Mechanistic core: Under normoxia, prolyl hydroxylases (PHD/EglN family) hydroxylate HIFα, enabling pVHL recognition and proteasomal degradation; VHL loss leads to HIF accumulation and transcriptional activation of pro-tumor programs. (gomezvirgilio2024geneticspathophysiologyand pages 11-13, kaelin2022vonhippel–lindaudisease pages 1-2)

2.2 Risk factors

  • Genetic: Carrying a germline VHL pathogenic variant is the dominant risk factor; penetrance of manifestations is reported as ~97% by age 65 in a 2024 review. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)
  • De novo mutations: Up to ~20% of cases may arise from new (de novo) mutations (review-level estimate). (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

2.3 Protective factors / gene–environment interactions

No explicit protective factors or gene–environment interaction data were identifiable in the retrieved evidence excerpts.

2.4 Modifier genes (emerging)

A 2023 case-based genetic analysis suggests that additional germline variants (e.g., CHEK2) may contribute to unusually severe hemangioblastoma burden in some families, consistent with a modifier model; however, this is currently case-report level and not established for broad risk stratification. (gomezvirgilio2024geneticspathophysiologyand pages 11-13)

3. Phenotypes (clinical spectrum)

3.1 Major tumor/lesion types (with frequencies where available)

From a 2024 U.S. claims-based study (background frequencies drawn from prior literature in that paper): - CNS hemangioblastoma: occurs in ~70–80% of cases; described as “typically the first manifestation.” (jonasch2024epidemiologyandeconomic pages 1-2) - Pancreatic neuroendocrine tumors (pNET): occur in ~9–17% of cases. (jonasch2024epidemiologyandeconomic pages 1-2)

From a 2023 cohort/review focused on VHL-related pancreatic neuroendocrine tumor and diagnostic criteria: - vPNET prevalence across cohorts reported as ~5% on average, up to 17% in some cohorts. (halperin2023uniquecharacteristicsof pages 1-2)

Additional classic manifestations described across sources include retinal hemangioblastomas, clear-cell RCC, pheochromocytoma/paraganglioma (PPGL), pancreatic cystic lesions, endolymphatic sac tumors, and reproductive-tract cystadenomas. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, halperin2023uniquecharacteristicsof pages 1-2)

3.2 Onset and progression (selected quantitative data)

  • Review-level estimate: median age of onset 26 years. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)
  • Pediatric PPGL registry data: mean age at first PPGL 12.4 ± 0.41 years (range 4–18); recurrences were common (46%). (kotsis2024surveillanceinchildren pages 1-2)

3.3 Quality-of-life impacts

While the excerpts do not include validated QoL scales (e.g., SF-36/EQ-5D), the 2024 claims-based analysis and pediatric registry data emphasize high healthcare utilization, repeated procedures, and recurrence (especially PPGL), implying significant burden and care intensity. (jonasch2024epidemiologyandeconomic pages 1-2, kotsis2024surveillanceinchildren pages 1-2)

3.4 Suggested HPO terms (non-exhaustive; based on explicitly mentioned manifestations)

  • CNS hemangioblastoma (HP term suggestion): Hemangioblastoma
  • Retinal hemangioblastoma: Retinal hemangioblastoma / retinal capillary hemangioma
  • Clear cell renal cell carcinoma: Renal cell carcinoma
  • Pheochromocytoma/paraganglioma: Pheochromocytoma, Paraganglioma
  • Pancreatic neuroendocrine tumor: Pancreatic neuroendocrine tumor

Note: Specific HPO IDs were not present in the retrieved excerpts; mapping to exact HP identifiers would require HPO lookup outside the retrieved papers.

4. Genetic / Molecular Information

4.1 Causal gene

  • VHL (tumor suppressor); gene OMIM *608537 (alvarez2024germlinevariantsin pages 1-2).

4.2 Variant spectrum and inheritance

  • Inheritance: autosomal dominant (explicitly stated in multiple sources). (gomezvirgilio2024geneticspathophysiologyand pages 1-2, alvarez2024germlinevariantsin pages 1-2)
  • Variant classes: reviews describe deletions and mutations and emphasize two-hit inactivation as the tumorigenic mechanism. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

4.3 Penetrance and expressivity

  • Review-level estimate: ~97% penetrance by age 65. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

4.4 Somatic vs germline

  • Germline VHL alteration defines inherited VHL disease; tumors typically arise after somatic inactivation of the remaining allele (loss of heterozygosity concept is discussed in mechanistic reviews). (ohh2022hypoxiainduciblefactorunderlies pages 1-2)

5. Environmental Information

No clear environmental/lifestyle/infectious triggers were identified in the retrieved evidence excerpts as causal or modifying factors for VHL disease.

6. Mechanism / Pathophysiology (causal chains; upstream→downstream)

6.1 Canonical pVHL–HIF axis (core mechanism)

Upstream trigger: germline VHL loss-of-function variant + somatic “second hit” in susceptible cells (tumor suppressor model). (kaelin2022vonhippel–lindaudisease pages 1-2, ohh2022hypoxiainduciblefactorunderlies pages 1-2)

Core molecular mechanism: pVHL is the substrate-recognition subunit of a Cullin2-based E3 ubiquitin ligase that targets hydroxylated HIFα for proteasomal degradation in oxygen-dependent fashion; VHL loss stabilizes HIFα, especially HIF2α. (kaelin2022vonhippel–lindaudisease pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

Downstream consequences: stabilized HIFα translocates to the nucleus, dimerizes with HIFβ, and activates gene expression programs promoting angiogenesis, altered metabolism, and tumor growth, helping explain the vascular nature of many VHL-associated tumors. (gomezvirgilio2024geneticspathophysiologyand pages 11-13)

Therapeutic connection: VEGF pathway inhibitors are a mainstay of ccRCC treatment; an allosteric HIF2 inhibitor (belzutifan) is approved for VHL-associated ccRCC based on this mechanistic dependency. (kaelin2022vonhippel–lindaudisease pages 1-2)

6.2 mTORC1 activation via pVHL loss (HIF-independent link)

A review and supporting primary data describe a HIF-independent mechanism: VHL can repress RAPTOR and thereby inhibit mTORC1 signaling; loss of VHL derepresses mTORC1, which is frequently hyperactivated in ccRCC. (ganner2021vhlsuppressesraptor pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

6.3 2024 mechanistic development: VHL control of m6A RNA methylation (HIF-independent)

A 2024 JCI mechanistic study reports that VHL binds and promotes METTL3/METTL14 complex formation; VHL depletion suppresses m6A modification. The study identifies PIK3R3 as a VHL–m6A-regulated target whose mRNA stability is controlled in an m6A-dependent but HIF-independent manner; PIK3R3 suppresses renal tumor growth by restraining PI3K/AKT signaling. (zhang2024vonhippellindau pages 1-2)

6.4 Suggested pathway/ontology terms (based on mechanisms described)

  • GO Biological Process (suggestions): hypoxia response / oxygen sensing; ubiquitin-dependent protein catabolic process; regulation of angiogenesis; regulation of mTOR signaling; RNA methylation (m6A); PI3K/AKT signaling regulation.
  • Cell types (CL suggestions): renal tubular epithelial cells; chromaffin cells (for PPGL); retinal vascular-associated cells; CNS vascular-associated stromal cells.

Exact GO/CL identifiers were not present in the retrieved excerpts and would require ontology lookup.

7. Anatomical Structures Affected (multi-organ)

Across sources, VHL disease affects: - CNS (brain/spinal cord): CNS hemangioblastomas (jonasch2024epidemiologyandeconomic pages 1-2) - Eye/retina: retinal hemangioblastomas (halperin2023uniquecharacteristicsof pages 1-2) - Kidney: cysts and clear-cell RCC (halperin2023uniquecharacteristicsof pages 1-2) - Pancreas: pancreatic lesions including pNETs and serous cystadenomas (else2024belzutifanforvon pages 5-6) - Adrenal/paraganglia: pheochromocytoma/paraganglioma (halperin2023uniquecharacteristicsof pages 1-2)

8. Temporal Development (onset, course)

  • Manifestations may begin in childhood/adolescence (e.g., PPGL, CNS lesions), with progressive emergence of additional lesions over time and frequent need for serial interventions. (kotsis2024surveillanceinchildren pages 1-2, knoblauch2024screeningandsurveillance pages 1-2)

9. Inheritance and Population

9.1 Epidemiology (recent data and statistics)

Disease-level prevalence estimates (review): prevalence described as approximately 1 in 36,000 worldwide in a 2024 review; another estimate range given is 1 in 39,000 to 1 in 91,000. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 22-24)

U.S. real-world prevalence for selected VHL manifestations (claims-based, 2019): - VHL-associated CNS hemangioblastoma: 1.12 per 100,000 (estimated 3,678 patients) - VHL-associated pancreatic NET: 0.12 per 100,000 (estimated 389 patients) (jonasch2024epidemiologyandeconomic pages 1-2)

9.2 Penetrance

  • ~97% by age 65 (review-level). (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

10. Diagnostics

10.1 Clinical diagnostic criteria (recent comparative analysis)

A 2023 study highlights that VHL can be clinically diagnosed via differing criteria sets (International vs Danish) and argues for genetic testing to improve diagnostic accuracy, especially in visceral-only presentations. In their cohort, vPNET patients meeting International Criteria had 90% germline VHL PV and 70% family history vs 20% and 10% in Danish-only cases. (halperin2023uniquecharacteristicsof pages 1-2)

10.2 Imaging and screening/surveillance (recent consensus and cohorts)

Updated pediatric/adolescent surveillance recommendations (2023 AACR workshop update summarized in 2025)

  • Blood pressure: at all visits starting at 2 years (rednam2025updateonsurveillance pages 8-10)
  • PPGL biochemistry: annual fractionated metanephrines starting at 5 years (plasma or 24-hour urine) (rednam2025updateonsurveillance pages 8-10, rednam2025updateonsurveillance pages 11-13)
  • Abdominal MRI (RCC/PanNET): contrast MRI every 2 years starting at 15 years (rednam2025updateonsurveillance pages 11-13, rednam2025updateonsurveillance pages 13-13)
  • Brain/spine MRI: recommendations vary by consensus group; once started, biennial imaging is consistently supported (rednam2025updateonsurveillance pages 8-10)
  • Ophthalmology: at least annual examinations from diagnosis; in younger children, as often as every 6 months may be considered (rednam2025updateonsurveillance pages 8-10)
  • Audiology: strategies differ (e.g., biennial from 11 years vs annual age 5–13 then biennial) (rednam2025updateonsurveillance pages 8-10)

2024 pediatric CNS cohort evidence

A 2024 pediatric cohort recommends starting CNS MRI at 12 years with intervals every (1–)2 years depending on involvement; truncating variants showed higher manifestation and surgery rates (HR 3.7 and 3.3). (knoblauch2024screeningandsurveillance pages 1-2)

10.3 Biomarkers/labs

The surveillance update explicitly uses fractionated metanephrines (plasma or urine) as screening biochemistry for PPGL beginning at age 5. (rednam2025updateonsurveillance pages 11-13)

11. Outcome / Prognosis

  • A 2023 clinical/review source notes leading causes of death as CNS hemangioblastoma followed by RCC (cohort/review-level statement). (halperin2023uniquecharacteristicsof pages 1-2)
  • The 2024 U.S. claims study demonstrates substantial healthcare utilization and higher annual costs relative to controls, reflecting chronic morbidity and repeated interventions. (jonasch2024epidemiologyandeconomic pages 1-2)

Survival curves and life expectancy estimates were not present in the retrieved excerpts.

12. Treatment

12.1 Standard interventions (real-world implementation)

For selected lesion types, management commonly involves surveillance with intervention thresholds: - CNS hemangioblastoma: active surveillance for asymptomatic lesions; surgery for symptomatic or CSF-obstructing lesions (as summarized in the 2024 claims-based study background). (jonasch2024epidemiologyandeconomic pages 1-2) - pNET: lesions >2–3 cm recommended for surgical removal (background statement in 2024 claims-based study). (jonasch2024epidemiologyandeconomic pages 1-2)

12.2 Targeted systemic therapy — HIF-2α inhibition (belzutifan)

Mechanistic rationale: HIF2 drives VHL-defective ccRCC growth; HIF2 inhibition is mechanistically aligned with the central VHL pathway. (kaelin2022vonhippel–lindaudisease pages 1-2)

Key 2024 clinical trial evidence (pancreatic lesions, LITESPARK-004): - Study: single-arm phase 2 LITESPARK-004 (NCT03401788), belzutifan 120 mg once daily. (else2024belzutifanforvon pages 5-6) - Pancreatic lesion population: 61/61 (100%) had ≥1 pancreatic lesion; 22/61 (36%) had measurable pNET at baseline; median follow-up 37.8 months. (else2024belzutifanforvon pages 5-6) - Objective response rate (ORR): pancreatic lesions 84% (51/61) with 17 complete responses; pNETs 91% (20/22) with 7 complete responses. (else2024belzutifanforvon pages 5-6) - Safety: 18% had ≥1 grade 3 treatment-related AE; no grade 4/5 treatment-related AEs reported. (else2024belzutifanforvon pages 5-6)

Real-world relevance: A 2024 U.S. claims analysis highlights the high costs of surgery for VHL-CNS hemangioblastoma and VHL-pNET, providing a health-economic rationale for effective medical therapies that could reduce surgical frequency/burden. (jonasch2024epidemiologyandeconomic pages 1-2)

12.3 Suggested treatment ontology terms

  • CHEBI (example): belzutifan (small-molecule HIF-2α inhibitor; CHEBI ID not provided in excerpts)
  • MAXO (suggestions): MRI surveillance; surgical resection; tumor ablation; targeted molecular therapy (HIF-2α inhibition); biochemical screening (metanephrines).

13. Prevention

13.1 Primary prevention

Not applicable in the classic infectious/toxic exposure sense; VHL is a genetic condition.

13.2 Secondary prevention (surveillance as prevention of complications)

The updated pediatric/adolescent surveillance framework (blood pressure, metanephrines, eye exams, MRIs) is a central preventive strategy intended to enable early detection and timely intervention. (rednam2025updateonsurveillance pages 8-10, rednam2025updateonsurveillance pages 11-13, rednam2025updateonsurveillance pages 13-13, knoblauch2024screeningandsurveillance pages 1-2)

14. Other species / natural disease

No naturally occurring non-human VHL disease analogs were identified in the retrieved excerpts.

15. Model organisms

Evidence excerpts supporting models/mechanistic conservation include: - C. elegans: loss of vhl-1 increased mTORC1 activity, supporting evolutionary conservation of VHL–mTORC1 regulation. (ganner2021vhlsuppressesraptor pages 1-2)

Detailed mouse/zebrafish models for VHL-associated tumor phenotypes were not available in the retrieved evidence excerpts used for citations in this report.

Recent developments (2023–2024 highlights)

  1. Claims-based U.S. epidemiology and economic burden (Feb 2024): prevalence estimates for VHL-CNS hemangioblastoma and VHL-pNET in 2019 and quantification of excess annual costs (+$49,645 and +$56,580, respectively). (jonasch2024epidemiologyandeconomic pages 1-2)
  2. Belzutifan efficacy in VHL pancreatic lesions (Feb 2024): high ORR/CR rates in pancreatic lesions and measurable pNETs with long follow-up and manageable safety. (else2024belzutifanforvon pages 5-6)
  3. HIF-independent pVHL mechanism via m6A (Apr 2024): VHL regulation of METTL3/METTL14 complex formation and m6A-dependent stabilization of PIK3R3 as a brake on PI3K/AKT-driven tumorigenesis. (zhang2024vonhippellindau pages 1-2)

Embedded quantitative summary table

Topic Key data (numbers) Population/setting Source (first author, year, journal) DOI/URL
Population prevalence / penetrance / onset Worldwide prevalence ≈ 1 in 36,000; median age of onset 26 years; penetrance of manifestations ~97% by age 65; up to 20% de novo cases (gomezvirgilio2024geneticspathophysiologyand pages 1-2) Disease-level review of VHL syndrome Gómez-Virgilio, 2024, Diagnostics https://doi.org/10.3390/diagnostics14171909
Alternative prevalence estimates Prevalence estimated 1 in 39,000 to 1 in 91,000 (gomezvirgilio2024geneticspathophysiologyand pages 22-24) Disease-level review Gómez-Virgilio, 2024, Diagnostics https://doi.org/10.3390/diagnostics14171909
Major phenotype frequencies CNS hemangioblastoma occurs in 70–80% of cases; pancreatic NETs in 9–17% (jonasch2024epidemiologyandeconomic pages 1-2) U.S. claims-based epidemiology background summary Jonasch, 2024, Orphanet Journal of Rare Diseases https://doi.org/10.1186/s13023-024-03060-w
vPNET frequency and mortality context vPNET prevalence averages ~5%, up to 17% in some cohorts; leading causes of death reported as CNS hemangioblastoma then RCC (halperin2023uniquecharacteristicsof pages 1-2) Cohort and review of diagnostic criteria in VHL patients with pNET comparison Halperin, 2023, Cancers https://doi.org/10.3390/cancers15061657
U.S. real-world prevalence of VHL manifestations 2019 prevalence: VHL-associated CNS hemangioblastoma 1.12/100,000 (3,678 patients); VHL-associated pNET 0.12/100,000 (389 patients) (jonasch2024epidemiologyandeconomic pages 1-2) Optum Clinformatics claims, United States Jonasch, 2024, Orphanet Journal of Rare Diseases https://doi.org/10.1186/s13023-024-03060-w
Economic burden Annual healthcare costs vs controls: VHL-CNS-Hb +$49,645; VHL-pNET +$56,580 (jonasch2024epidemiologyandeconomic pages 1-2) U.S. matched claims cohorts: VHL-CNS-Hb N=220; VHL-pNET N=20 Jonasch, 2024, Orphanet Journal of Rare Diseases https://doi.org/10.1186/s13023-024-03060-w
Diagnostic criteria cohort data Among vPNET patients meeting International Criteria: germline VHL pathogenic variant 90% and family history 70% vs Danish-only group 20% and 10%; vPNET diagnosis age 51.6 ± 4.1 vs sporadic PNET 62.8 ± 1.5 years (halperin2023uniquecharacteristicsof pages 1-2) 33 VHL patients (20 vPNET) and 65 sporadic PNET comparators Halperin, 2023, Cancers https://doi.org/10.3390/cancers15061657
Pediatric PPGL timing / recurrence Mean age at first PPGL 12.4 ± 0.41 years (range 4–18); recurrence 46%; other tumors during follow-up: hemangioblastomas 73%, retinal angiomas 58%, RCC 21%, pNET 12% (kotsis2024surveillanceinchildren pages 1-2) German pediatric/adolescent VHL registries, 75 patients Kotsis, 2024, Journal of Kidney Cancer and VHL https://doi.org/10.15586/jkcvhl.v11i4.362
Pediatric CNS hemangioblastoma surveillance Start MRI at age 12 years; repeat every 1–2 years depending on CNS involvement; truncating variants had higher manifestation rate (HR 3.7, 95% CI 1.9–7.4) and surgery rate (HR 3.3, 95% CI 1.2–8.9) (knoblauch2024screeningandsurveillance pages 1-2) Monocentric pediatric cohort, 99 VHL patients Knoblauch, 2024, Journal of Neuro-Oncology https://doi.org/10.1007/s11060-024-04676-5
Updated pediatric/adolescent surveillance: blood pressure & PCC biochemistry Blood pressure at all visits starting at 2 years; annual fractionated metanephrines starting at 5 years; test for PCC before major surgery (rednam2025updateonsurveillance pages 8-10, rednam2025updateonsurveillance pages 11-13) 2023 AACR Childhood Cancer Predisposition Workshop update summarized in 2025 perspective Rednam, 2025, Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-24-3525
Updated surveillance: ophthalmology / audiology / neuroimaging Eye exams at least annually from diagnosis; in younger children, every 6 months may be considered. Audiograms: biennial from 11 years (Daniels) or annual age 5–13 then biennial (Binderup). Brain/spine MRI: baseline at 10 years then, if negative, resume at 15 years and continue biennially, or begin biennial MRI at 11 years depending on guideline set (rednam2025updateonsurveillance pages 8-10) Comparative consensus recommendations summarized in AACR update Rednam, 2025, Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-24-3525
Updated surveillance: abdominal MRI Contrast abdominal MRI for RCC/PanNET every 2 years starting at 15 years (rednam2025updateonsurveillance pages 11-13, rednam2025updateonsurveillance pages 13-13) Pediatric/adolescent surveillance update Rednam, 2025, Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-24-3525
Local pediatric registry surveillance practice Annual hormone measurements; eye exam starting at 6 years; CNS/abdominal MRI starting at 12 years; regular screening may begin at 5 years in known variant families; intervals 1–2 years depending on stage/risk (kotsis2024surveillanceinchildren pages 1-2) Freiburg-VHL screening/surveillance program Kotsis, 2024, Journal of Kidney Cancer and VHL https://doi.org/10.15586/jkcvhl.v11i4.362
Belzutifan phase 2 trial design LITESPARK-004 / NCT03401788; adults with germline VHL alteration; 61 patients enrolled; belzutifan 120 mg once daily; endpoints included ORR, DOR, PFS, linear growth rate, safety (else2024belzutifanforvon pages 5-6) Single-arm phase 2 VHL disease study Else, 2024, Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-23-2592
Belzutifan pancreatic lesion efficacy All 61/61 (100%) had ≥1 pancreatic lesion; 22/61 (36%) had measurable pNET at baseline; median follow-up 37.8 months; ORR 84% (51/61) in pancreatic lesions with 17 complete responses; ORR 91% (20/22) in pNETs with 7 complete responses; median pNET linear growth rate −4.2 mm/year; grade 3 treatment-related AEs 18%; no grade 4/5 treatment-related AEs (else2024belzutifanforvon pages 5-6) Pancreatic lesion population of LITESPARK-004 Else, 2024, Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-23-2592

Table: This table compiles the key 2023-2025 quantitative findings and surveillance recommendations extracted so far for von Hippel–Lindau disease. It emphasizes epidemiology, phenotype frequency, pediatric surveillance timing, and belzutifan phase 2 efficacy data relevant for a disease knowledge base.

Notes on evidence limitations (for knowledge base curation)

  • Many requested ontology IDs (MONDO, MeSH, Orphanet) and some phenotype-specific HPO IDs were not explicitly present in the accessible excerpts and therefore could not be safely asserted here.
  • Survival/life expectancy statistics and standardized QoL instrument outcomes were not present in the retrieved excerpts.
  • While belzutifan and surveillance are strongly supported with recent data, quantitative outcomes for many local interventions (e.g., stereotactic radiosurgery, ablation modalities) were not available in the extracted evidence.

References

  1. (gomezvirgilio2024geneticspathophysiologyand pages 1-2): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

  2. (alvarez2024germlinevariantsin pages 1-2): Antonio Alejandro Esperón Álvarez, Inés Virginia Noa Hechavarría, Ixchel López Reyes, and Teresa Collazo Mesa. Germline variants in the von hippel-lindau tumor suppressor gene in cuban patients. Egyptian Journal of Medical Human Genetics, Mar 2024. URL: https://doi.org/10.1186/s43042-024-00506-5, doi:10.1186/s43042-024-00506-5. This article has 0 citations and is from a peer-reviewed journal.

  3. (kaelin2022vonhippel–lindaudisease pages 1-2): William G. Kaelin. Von hippel–lindau disease: insights into oxygen sensing, protein degradation, and cancer. The Journal of Clinical Investigation, Sep 2022. URL: https://doi.org/10.1172/jci162480, doi:10.1172/jci162480. This article has 151 citations.

  4. (jonasch2024epidemiologyandeconomic pages 1-2): Eric Jonasch, Yan Song, Jonathan Freimark, Richard Berman, Ha Nguyen, James Signorovitch, and Murali Sundaram. Epidemiology and economic burden of von hippel-lindau disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the united states. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03060-w, doi:10.1186/s13023-024-03060-w. This article has 7 citations and is from a peer-reviewed journal.

  5. (else2024belzutifanforvon pages 5-6): Tobias Else, Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Jodi K. Maranchie, Ane B. Iversen, Cynthia M. Goldberg, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, and Ramaprasad Srinivasan. Belzutifan for von hippel-lindau disease: pancreatic lesion population of the phase 2 litespark-004 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:1750-1757, Feb 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-2592, doi:10.1158/1078-0432.ccr-23-2592. This article has 26 citations.

  6. (zhang2024vonhippellindau pages 1-2): Cheng Zhang, Miaomiao Yu, Austin J. Hepperla, Zhao Zhang, Rishi Raj, Hua Zhong, Jin Zhou, Lianxin Hu, Jun Fang, Hongyi Liu, Qian Liang, Liwei Jia, Chengheng Liao, Sichuan Xi, Jeremy M. Simon, Kexin Xu, Zhijie Liu, Yunsun Nam, Payal Kapur, and Qing Zhang. Von hippel lindau tumor suppressor controls m6a-dependent gene expression in renal tumorigenesis. The Journal of Clinical Investigation, Apr 2024. URL: https://doi.org/10.1172/jci175703, doi:10.1172/jci175703. This article has 13 citations.

  7. (hochberg2024isthetrinetx pages 1-2): Aaron R. Hochberg, Patrick T. Gomella, Brian Im, Anushka Ghosh, Sohan Shah, Rasheed A.M. Thompson, Kevin K. Zarrabi, Mihir S. Shah, J. Ryan Mark, Joseph K. Izes, Costas D. Lallas, Leonard G. Gomella, and Adam R. Metwalli. Is the trinetx database a good tool for investigation of real-world management of von hippel–lindau? Journal of Kidney Cancer and VHL, 11:28-38, Dec 2024. URL: https://doi.org/10.15586/jkcvhl.v11i4.324, doi:10.15586/jkcvhl.v11i4.324. This article has 4 citations.

  8. (gomezvirgilio2024geneticspathophysiologyand pages 11-13): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

  9. (halperin2023uniquecharacteristicsof pages 1-2): Reut Halperin, Liat Arnon, Yehudit Eden-Friedman, and Amit Tirosh. Unique characteristics of patients with von hippel–lindau disease defined by various diagnostic criteria. Cancers, 15:1657, Mar 2023. URL: https://doi.org/10.3390/cancers15061657, doi:10.3390/cancers15061657. This article has 9 citations.

  10. (kotsis2024surveillanceinchildren pages 1-2): Fruzsina Kotsis, Marina Kunstreich, Antje Redlich, Kilian Rhein, Athina Ganner, Gerd Walz, Michaela Kuhlen, and Elke Neumann-Haefelin. Surveillance in children and adolescents with von hippel-lindau (vhl)-related pheochromocytomas and paragangliomas: a survey of met and freiburg-vhl registries in germany. Journal of Kidney Cancer, 11:15-27, Nov 2024. URL: https://doi.org/10.15586/jkcvhl.v11i4.362, doi:10.15586/jkcvhl.v11i4.362. This article has 0 citations.

  11. (ohh2022hypoxiainduciblefactorunderlies pages 1-2): Michael Ohh, Cassandra C Taber, Fraser G Ferens, and Daniel Tarade. Hypoxia-inducible factor underlies von hippel-lindau disease stigmata. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.80774, doi:10.7554/elife.80774. This article has 34 citations and is from a domain leading peer-reviewed journal.

  12. (ganner2021vhlsuppressesraptor pages 1-2): Athina Ganner, Christina Gehrke, Marinella Klein, Lena Thegtmeier, Tanja Matulenski, Laura Wingendorf, Lu Wang, Felicitas Pilz, Lars Greidl, Lisa Meid, Fruzsina Kotsis, Gerd Walz, Ian J. Frew, and Elke Neumann-Haefelin. Vhl suppresses raptor and inhibits mtorc1 signaling in clear cell renal cell carcinoma. Scientific Reports, Jul 2021. URL: https://doi.org/10.1038/s41598-021-94132-5, doi:10.1038/s41598-021-94132-5. This article has 40 citations and is from a peer-reviewed journal.

  13. (knoblauch2024screeningandsurveillance pages 1-2): Anna Laura Knoblauch, Bianca-Ioana Blaß, C. Steiert, N. Neidert, A. Puzik, E. Neumann-Haefelin, A. Ganner, F. Kotsis, T. Schäfer, H.P.H. Neumann, S. Elsheikh, J. Beck, and Jan-Helge Klingler. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with von hippel-lindau disease. Journal of Neuro-Oncology, 168:537-545, Apr 2024. URL: https://doi.org/10.1007/s11060-024-04676-5, doi:10.1007/s11060-024-04676-5. This article has 5 citations and is from a peer-reviewed journal.

  14. (gomezvirgilio2024geneticspathophysiologyand pages 22-24): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

  15. (rednam2025updateonsurveillance pages 8-10): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.

  16. (rednam2025updateonsurveillance pages 11-13): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.

  17. (rednam2025updateonsurveillance pages 13-13): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.